

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Exhibit G

JEFFREY S. ROSS, M.D.

Department of Pathology and Laboratory Medicine
Albany Medical Center
47 New Scotland Avenue (mail code-81)
Albany, New York 12208
Telephone (518) 262-5471
Fax (518) 262-8092
email: rossj@mail.amc.edu

PERSONAL INFORMATION:

Home Address: 7 Bird Road
Lebanon Springs, New York 12125

Date of Birth: September 30, 1945

Citizenship: U.S.A.

Social Security: 032-36-7734

EDUCATION:

College: Oberlin College, Oberlin, Ohio
B.A. 1966

Medical School: SUNY at Buffalo, School of Medicine
M.D. 1970

POST GRADUATE TRAINING:

1970-1971 Intern in Pathology
Massachusetts General Hospital
Boston, Massachusetts

1971-1974 Resident in Pathology
Massachusetts General Hospital
Boston, Massachusetts

1971-1974 Research Fellow in Surgery
Shriners Burn Institute
Boston, Massachusetts

1972-1974 Teaching Fellow in Pathology
Harvard Medical School
Boston, Massachusetts

LICENSURE:

1972 Commonwealth of Massachusetts #33800
1974 State of South Carolina #7612
1981 State of Vermont
1989 State of New York #170400

CERTIFICATIONS:

1971	National Board of Medical Examiners
1974	American Board of Pathology
	Anatomic and Clinical Pathology

PROFESSIONAL EXPERIENCE:

1974-1975	Assistant Chief, Department of Pathology, Moncrief Army Hospital, Fort Jackson, South Carolina
1975-1976	Chief, Department of Pathology, Moncrief Army Hospital, Fort Jackson, South Carolina
1976-1979	Associate in Pathology and Director of Anatomic Pathology, Berkshire Medical Center, Pittsfield Massachusetts
1978-1983	Teaching Fellow in Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
1976	Assistant Professor of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts
1976 - 1979	Instructor of Pathology, Albany Medical College, Albany, New York
1976	Visiting Pathologist, Department of Pathology, Sheba Medical Center, Tel-Hashomer, Israel
1976	Director, School of Cytotechnology, Berkshire Medical Center, Pittsfield, Massachusetts
1979-1984	Clinical Assistant Professor, Albany Medical College, Albany, New York
1980-1982	Secretary-Treasurer, Medical Staff, Berkshire Medical Center, Pittsfield, Massachusetts
1983-1989	Clinical Associate in Pathology, Massachusetts General Hospital and Harvard Medical School, Member Massachusetts General Hospital Pathology Associates and Massachusetts General Hospital Professional Services Corporation
1984-1989	Assistant Director of Medical Education, Berkshire Medical Center
1984-1989	Assistant Dean for Student Affairs, University of Massachusetts Medical School at Berkshire Medical Center
1984-1989	Clinical Associate Professor of Pathology, Albany Medical College

1985-1988	Associate Professor of Pathology, University of Massachusetts Medical School
	Associate Professor of Obstetrics and Gynecology, University of Massachusetts Medical School
1988-1989	Professor of Pathology and Obstetrics and Gynecology, University of Massachusetts Medical School
1989 - Present	Chairman and Professor, Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York
1989-Present	Professor, Samuel Stratton Veterans Administration Medical Center, Albany, New York
1990 – 2000	Attending Pathologist, St. Clare's Hospital, Schenectady, New York
1991 - 1992	Director of Pathology and Laboratory Medicine, Attending Pathologist, Community Hospital of Schoharie County, Schoharie, New York
1991 - Present	Attending Pathologist, The Kingston Hospital, Kingston, New York
1991 - Present	Attending Pathologist, Benedictine Hospital, Kingston, New York
1991 – 2000	Director, Berkshire Physicians and Surgeons Central Laboratory, Pittsfield, Massachusetts
1992 - 1999	Consultant and Medical Director for Managed Care, Roche Biomedical Laboratories (Laboratory Corporation of America)
1992 - 1996	Consultant in Pathology, Roche Image Analysis Systems
1993 - Present	Attending Pathologist, St. Elizabeth Hospital, Utica, New York
1994	Faculty, Russell Sage College, Troy, New York
1994	University at Albany, State University of New York, Adjunct Professor
1995	Faculty, State University College of Arts and Sciences at Plattsburgh, NY
1996 - 1998	Medical Director, Oncor, Inc., Gaithersburg, MD
1998 - Present	Member, Scientific Advisory Board, Welch-Allyn Corporation, Skaneateles, NY
1998 - Present	Medical Director, Ventana Medical Systems, Inc., Tucson, AZ

1999 - Present	Consultant, Becton-Dickinson Gene, Inc., Sparks, MD
1999 - 2000	Scientific Fellow and Head, Molecular Pathology, Millennium Pharmaceuticals, Inc., Cambridge, MA (part-time sabbatical)
2000-Present	Vice President Molecular Medicine, Millennium Pharmaceuticals, Inc., Cambridge, MA

MEMBERSHIPS:

1970	New England Pathology Residents Society
1972	American Society of Clinical Pathologists (Education Committee 1994; Director, Education and Research Council 1995; Commissioner for Graduate Medical Education and Member, Board of Directors 1996 - present)
1973	International Academy of Pathology
1974	Columbia Regional Pathology Association
1975	American Society of Cytology (Chair, Practice Committee, 1995)
1976	Fellow, College of American Pathologists (Program and Program Evaluation Committee, 1997; Pathologist Workload Committee, 1997 – present; Education Committee 2000-present)
1976	Berkshire District Medical Society (President-elect, 1988)
1977	Massachusetts Medicolegal Society (Steering Committee, 1980; President, 1983)
1978	Massachusetts Cytology Society National Association of Medical Examiners New England Society of Pathologists
1981	Massachusetts Society of Pathologists
1984-1989	Member of Board, Berkshire Area Health Education Center (Vice President, 1985)
1987	International Society for Preventative Oncology (Program Committee, 1987)
1989	Association of Pathology Chairmen (Director Practice Committee 1993)
1992	American Association of Pathologists

1994	International Society of Urological Pathologists
1996	Association for Molecular Pathology
1996	American Association for Cancer Research
1997	College of American Pathologists Productivity Committee
1997	College of American Pathologists Program and Planning Committee
1997	International Academy of Tumor Marker Oncology Advisory Council
1999	American Urologic Association
2001	American Society of Clinical Oncologists
<u>AWARDS:</u>	
1966	Gibson Anatomical Society
1967	Mosby Corporation Fellowship Award
1968	National Board of Medical Examiners Special Honors
1969	Alpha Omega Alpha, Junior Election
1970	Bacelli Medical Research Award, Thesis Honors, Senior Scholarship Prize
1979	Massachusetts Medical Society Continuing Medical Education Award
1979, 1982, 1990	Albany Medical College Golden Apple Teaching Award Nominee
1996-Present	Citation in "Best Doctors in America"
1996	Albany Medical College Golden Apple Outstanding Teaching Award Recipient
2000	International Academy of Pathology Top Ten Pathology Research Departments in the World
2000	Member NIH Clinical Oncology Study Section
2001	Robert Hellman Lecture, University of Miami
2001	International Academy of Pathology Top Ten Pathology Research Departments in the World

2001	Center of Prostate Disease Research Award
2001	American Society of Clinical Oncology Merit Award
2002	International Academy of Pathology Top Ten Pathology Research Departments in the World
2003	Kornell Terplan Lecture, State University of New York at Buffalo, School of Medicine

PATENTS:

1997	U.S. Patent # 08/832,745 Use of Fluorescence <i>In-Situ</i> Hybridization in Assessing Prostatic Cancer
1999	U.S. Patent # 5994071 Prostate Cancer Prognosis with HER-2/ <i>neu</i>
2001	U.S. Patent # 6322986 Method for Colorectal Cancer Prognosis and Treatment Selection
2003	U.S. Patent Pending PSMA Prediction of Prostate Cancer Prognosis

NATIONAL WORKSHOPS AND COURSES:

Director, Advanced Course: Cerebrospinal Fluid Cytology with Immunohistochemical correlation. American Society of Cytology National Meetings 1986.

Co-Director, Advanced Course: Application of DNA Ploidy Determination and Cell Cycle Analysis in Surgical Pathology. American Society of Clinical Pathologists National Meeting 1992, 1993, 1994, 1999.

Co-Director, Advanced Course: DNA and Cell Cycle Analyses in Diagnostic Cytopathology. American Society of Cytology National Meeting 1994, 1995, 1996, 1997.

Co-Director, Workshop: The Pathobiology of Implants, Prostheses, and Retained Foreign Materials. American Society of Clinical Pathologists National Meeting 1994, 1995.

Director, Workshop: Pathology and Pathobiology of *Helicobacter Pylori* Associated Upper Gastrointestinal Disease. American Society of Clinical Pathologists National Meeting, 1996

Member, NIH/NCI Workshop on Prostate Cancer, 1996

Director, Short Course: Ancillary Techniques in Diagnostic Cytopathology: Uses and Limitations. United States and Canadian Academy of Pathology, Inc., 1998

Co-Director, Workshop: Differential Diagnosis and Clinical Significance of Lymphoid and Round Cell Infiltrates of the Skin. American Society of Clinical Pathologists National Meeting, 1998

Director, Workshop: Uses and Limitations of Ancillary Techniques in Diagnostic Cytopathology. United States and Canadian Academy of Pathology National Meeting, San Francisco, March 1999, New Orleans 2000

RESEARCH SUPPORT

1971-1973	American Cancer Society Fellowship (\$15,000 per year)
1973-1974	Pathology Training Grant 1-TO 1-6M 0221201 (\$15,000 per year)
1974-1976	US Army Active Duty US Army Direct Research Support
1976-1985	USPHS CA-17324 National Cancer Institute Experiment Colonic Carcinogenesis Co-Investigator (20% time) Ronald A. Malt MD, Principal Investigator
1976-1988	Stanley Thomas Johnson Foundation Co-Investigator (10% time) Ronald A. Malt, MD, Principal Investigator Colonic and Pancreatic Carcinogenesis
1988-1989	Oscar Pluznick Cancer Research Award University of Massachusetts Medical School (\$100,000 - returned when relocated)
1993	Immunex Corporation Helicobacter Pylori Animal Models (\$15,000)
1994	Roche Image Analysis Systems Development Grant (\$127,000 - purchase of Image Analysis Equipment)
1996	Oncor, Inc. HER-2/ <i>neu</i> Amplification in Breast Cancer by Fluorescence In-situ Hybridization J.S. Ross MD, Principal Investigator (\$30,000)

1996	Oncor, Inc. Gene Rearrangements in Lymphomas (\$110,000)
1996-1997	Proctor and Gamble Helicobacter Pylori and Gastric Ulcers (\$80,000)
1997	Oncor, Inc. p43 Expression in Breast Cancer - Placental Isoferritin (\$100,000)
1997	Oncor, Inc. HER-2/ <i>neu</i> Expression in Node Positive Breast Cancer (\$8,000)
1997	Oncor, Inc. Tumor Bank Development Grant (\$47,800)
1997	Oncor, Inc. Pathology Applications Grant (\$35,000)
1997	Cytec, Inc. Hormone Receptors in Breast Cancer Needle Aspirates (\$12,000)
1997	Ventana Medical Systems Automated In-situ Hybridization and Immunohistochemistry Development (\$36,000)
1998	Small Business Innovation Research Prostate Cancer Assay for Methylation Status of GST-pi 1 R43 CA 79281-01 Oncor, Inc Jeffrey S. Ross, MD, Co-Principal Investigator (\$93,326 Direct, 20% at AMC)
1998-1999	Oncor, Inc Pathology Applications Award Jeffrey S. Ross, MD, Principal Investigator (\$107,000)
1998	Ventana Medical Systems Automated In-situ Hybridization and Immunohistochemistry Continued Development Jeffrey S. Ross, MD, Principal Investigator (\$45,073, January - June 1998)

- 1998 Stryker Biotech/Department of Orthopaedics
Pathology GLP Services
Jeffrey S. Ross, MD, Principal Investigator
(\$17,920 January - June 1998)
- 1999 Department of Defense, Department of Army
Development of an Assay for Prostate Cancer Based on Methylation
Status of the Glutathione-S-Transferase-pi
PC 970380
Jeffrey S. Ross, MD, Principal Investigator
(\$184,277 Direct) March 1999 - March 2001
- 2000 Clinomics, Inc
(\$20,000 contract research GLP In situ Hybridization and
Immunohistochemistry)
- 2003 Tripath Oncology, Inc.
Melastatin CISH Clinical Outcome Study
(\$50,000)

EDITORIAL BOARDS

Associate Chief Editor for Basic Sciences *American Journal of Clinical Pathology*

Editorial Board *Cancer Detection and Prevention*

Editorial Board *Journal of Tumor Marker Oncology*

Editorial Board *Advances in Anatomic Pathology*

Editorial Board *Modern Pathology*

Editorial Advisory Panel *Expert Review of Molecular Diagnostics*

Regular Manuscript Reviewer for *Archives of Pathology and Laboratory Medicine, Cancer, Science, New England Journal of Medicine; International Journal of Cancer, Urology, Journal of Urology Journal of Molecular Medicine, International Journal of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research*

STUDY SECTIONS

- 1991-1993 California Tobacco Related Disease Research Young Investigators
Section
- 1994 NIH RFA Helicobacter Pylori and Cancer
- 1995 NIH NCI SPORE Program in Prostate Cancer
- 1995 NIH/RFA Bladder Cancer Biomarkers
- 1996 NIH NCI SPORE Colon and Pancreatic Carcinogenesis
- 1997 NIH/NCI Prostate Cancer
- 1998 US Army/DOD Prostate Cancer Centers

2000-2005	NIH Clinical Oncology Study Section
2001	NIH Genitourinary Cancer SPORE Study Section

TEXTBOOKS

1. Ross JS. DNA Ploidy and Cell Cycle Analysis in Pathology. Igaku-Shoin Medical Publishers, Inc., New York, 1996.
2. Foster CS, Ross JS, Pathology of the Urinary Bladder. WB Saunders, Inc., Philadelphia, 2003 (in press)
3. Ross JS, Hortobagyi GN. Molecular Oncology of Breast Cancer. Jones and Bartlett, Inc. Cambridge, 2004 (in preparation)

TEXTBOOK CHAPTERS

1. Ross JS: Experimental Large Intestinal Adenocarcinoma Induced by Hydrazines and Human Colorectal Cancer: A Comparative Study. *Colonic Carcinogenesis* London: MTP Press, Chapter 19, pp 108-18, 1982.
2. Li AKC, Schattenkerk ME, de Vries JE, Ross JS and Malt RA: Saliva as a Modifier of Dimethylhydrazine-induced Colorectal Cancer. In *Colonic Carcinogenesis* chapter 25, (RA Malt and RCN Williamson, eds) Boston: MTP Press, pp 261-271, 1982.
3. Ross JS and Nieburgs HE: Pathology of Colorectal Cancer. In *Das Colorktale Karzinom und Seine Pracanzerosen*. Izbicki, J.R. (ed.) 1990.
4. Ross JS and Nieburgs HE: Natural History of Cancerous and Precancerous Lesions of the Colon and Rectum. In *Das Colorktale Karzinom und Seine Pracanzerosen*. Izbicki, J.R. (ed.), 1989.
5. Ross JS: Kallakury BVS, Figge J. Pathology and Molecular Biology of Prostate Cancer. In Rifkin MD, *Ultrasound of the Prostate*, Second Edition, Lippincott Raven Publishers, New York 1997, pp179-190.
6. Ross JS. Errors and pitfalls in diagnostic cytology: New techniques applied to cytopathology. In LG Koss (editor), *IAP Monograph Volume 39*, Williams and Wilkens, Baltimore, 1997, pp 94-117.
7. Ross JS, Sheehan CE, Fletcher JA. HER-2/neu oncogene amplification determined by fluorescence in-situ hybridization. In *Molecular Pathology Protocols*. Anthony A. Killeen (ed), Humana Press, Totowa, NJ. 2000, pp 93-104.
8. Mihm MC, Sanchez-Carpintero I, Frangia K, Ross JS. Molecular pathology of melanoma. In *Surgical Pathology Update 2001, 18 European Congress of Ppathology*. S. Hauptmann, M. Dietel, M. Sobrinho-Simoes. ABW Wissenschaftsverlag, Berlin, 2001, pp353-355.
9. Kallakury BVS and Ross JS. Prognostic and Predictive Markers in Prostate Cancer. In *Prostate Cancer Biology, Diagnosis and Management*. Konstantinos Syrigos (ed), Oxford Medical Publications, NY, New York 2001, pp 192-208.

ABSTRACTS

1. Buchholz TW, Malamud D, Ross JS and Malt RA: Rapid Ileal Hyperplasia Induced by Total Colectomy. (Abstract) Clinical Research 23:392, 1975.
2. Malt RA, Nundy S, Szczerban J, Malmamud DF and Ross JS: Studies on Proliferative Response of Remaining Intestinal Cells to Partial Bowel Resection. (Abstract) Nat Can Inst Current Cancer Research, OCRDB L20 Sept. 76.
3. Williamson RCN, Bauer FLR, Ross JS, Malt RA. Trophic and Co-carcinogenic Actions of Pancreaticobiliary Secretions. (Abstract) Irish J Med Sci 146 (suppl):8, 1977.
4. Williamson RCN, Bauer FLR, Ross JS, Malt RA. Promotion of Intestinal Neoplasia by Postoperative Mucosal Hyperplasia. (Abstract). Digestion 16:284-285, 1977.
5. Williamson RCN, Bauer FL, Ross JS and Malt RA: Intestinal Hyperplasia Stimulated by Jejunectomy vs. Bypass or Pancreatobiliary Diversion. (Abstract) Clin Res 25:470, 1977.
6. Williamson RCN, Bauer FL, Ross JS and Malt RA: Adaptation of the Shortened Gut: The Role of Endogenous Secretion. (Abstract) Gut 19:455, 1978.
7. Williamson RCN, Bauer FL, Ross JS and Malt RA: Divergent Effects of Enteric Bypass, Enterectomy, and Colectomy on Azoxymethane-induced Carcinogenesis. (Abstract) Proc Am Assn Canc Res 20:18, 1979.
8. Williamson RCN, Bauer FL, Ross JS and Malt RA: Protective Effects of Jejuno-ileal Bypass in Experimental Intestinal Cancer. (Abstract) Br J Surg 66:363, 1979.
9. Li AKC, Schattenkerk ME, Huffman RG, Ross JS, Malt RA. Submandibular Saliva Promotes Small Bowel Intestinal Proliferation. (Abstract) Clin Res 28:483A, 1980.
10. Terpstra OT, Peterson Dahl E, Ross JS, Williamson RCN, Malt RA. Restoration of Colonic Continuity Promotes Distal Colon Cancer Induced by Dimethylhydrazine. (Abstract) Europ J Surg Res 15:40-41, 1980.
11. Ford WDA, de Vries JE, King WWK, Boelhower RU, Kleinman RE, Ross JS, Malt RA. Decrease of Bovine Serum Albumin Absorption and Increases in Sucrase Specific Activity and in Cell Size Follow Mid-small-bowel Resection in the Neonatal Rat. (Abstract) Aust Ped J 17:236-237, 1981.
12. Oscarson JEA, Veen HF, Ross JS, Malt RA. Independence of Colonic Mucosa and Dimethylhydrazine-induced (DMH) Carcinoma From Physiologic Levels of Serum Gastrin. (Abstract) Gastroenterol 80:1245, 1981.
13. Kingsnorth AN, King WWK, McCann PP, Diekema K, Ross JS, Malt RA. Difluoromethylornithine (DFMO) Diminishes 1,2-dimethylhydrazine-induced (DMH) Colonic Carcinogenesis in Mice. (Abstract) Gastroenterol 82:1100, 1982.
14. Ford WDA, de Vries JE, Boelhouwer RU, King WWK, Ross JS, Malt RA. Breast Milk from Mothers that Have Recently Given Birth Stimulates Distal Villous Growth after Proximal Intestinal Resection in Neonatal Rats. (Abstract) Aust NZ J Surg 52:281, 1982.

15. Kingsnorth AN, Abu-Khalaf M, LaMuraglia GM, McCann PP, Diekema KA, Ross JS and Malt RA: Breakthrough Postresectional Ileal and Colonic Hyperplasia After Inhibition of Ornithine Decarboxylase Activity in Rats. (Abstract) *Gastroenterol* 86:1135, 1984.
16. Ford WDA, Boelhouwer RU, King WWK, de Vries JE, Ross JS, Malt RA. Postresectional Intestinal Hyperplasia Inhibited by Total Parenteral Nutrition: Reversibility by Oral Feedings in Young Rats. (Abstract) *Fed Proc* 43:1103, 1984.
17. Chester JF, Ross JS, Malt RA, Weitzman SA. Acute Colitis Produced by Chemotactic Peptides in the Mouse. (Abstract) *Gastroenterol* 88:1348, 1985.
18. Chester JF, Gaissert HA, Ross JS, Malt RA. Promotion on N-nitrosobis (2-Oxopropyl)amine (BOP)-induced Pancreatic and Bronchial Cancer by Epidermal Growth Factor in the Syrian Hamster. (Abstract) *Cancer Res* 26:121, 1985.
19. Ross JS, Chester JF, Gaissert HA, Weitzman SA and Malt RA: Morphology Aspects of the Experimental Production of Acute Colitis and Augmentation of Colonic Carcinogenesis by Formylated Peptides. *Lab Invest* 1986.
20. Ross JS, Bui HX, del Rosario A, Sonbati H, George M, Lee CY: *Helicobacter Pylori* - Its Role in the Pathogenesis of Peptic Ulcer Disease in a New Animal Model. *Lab Invest* (Abstract) 64:40, 1991.
21. Ballouk F, Ross JS, Malfetano J: DNA Ploidy in Vulvar and Vaginal Squamous Cell Carcinoma. *Lab Invest* (Abstract) 64(1):54, 1991.
22. Ross JS, Samaan S, Ruckdeschel J, Wagner-H, Boguniewicz A: DNA Ploidy in Atypical Carcinoid Tumors of the Lung. *Lab Invest* (Abstract) 64:118A, 1991
23. Ross JS, Bakst G, Weisheit D, Solis O, Goodman AD, Figge J: Distribution of Retinoblastoma Anti-oncogene Product in Human Normal Adrenal Medulla and Pheochromocytomas. (Abstract) *Lab Invest* 64:33A, 1991.
24. Veloso JD, Solis O, Barada JH, Fisher HAG, Ross JS: DNA Ploidy of Renal Oncocytomas and Renal Cell Carcinomas by Image Analysis. (Abstract) *Lab Invest*, 64(1):53A, 1991.
25. Veloso JD, Barada JH, Solis OG, Ross JS, Fisher HAG, Bennett AH. Image analysis of renal cell carcinoma and renal oncocytomas. (Abstract) Presented at the American Urological Association Annual Meeting, Toronto, Canada, 1991.
26. Kim DN, Schmee J, Lee CS, Eastman A, Ross JS, Thomas WA. Fish Oils Reduce Platelet-Monocyte-Endothelial Cell Interactions Over Lesions of Coronary Arteries in Swine. 64th Scientific Sessions, American Heart Association, (Abstract), 1991.
27. Bui HX, Ross JS, del Rosario AD, Sonbati H, Lee CY, George M. *Helicobacter Pylori* Affects the Quality of Experimental Gastric Ulcer Healing: A Qualintative and Quantitative Histologic Analysis in a New Animal Model. (Abstract) *Lab Invest* 64(1):34A, 1991.

28. Ross JS, Nazeer T, Rosano TG, Malfetano J. Correlation of Tumor Cytosol Cathepsin D with Differentiation and Invasiveness of Endometrial Adenocarcinoma. (Abstract) Lab Invest 64(1):60A, 1991.
29. Bui HX, del Rosario AD, Khan M, Abdulla M, Martini J, Lee CY, Ross JS. Evolution and Healing of Duodenal Ulcer in a New Experimental Model. (Abstract) Modern Pathol 5(1): A229, 1992.
30. Ross JS, Bui HX, del Rosario AD, Abdulla M, Khan M, George M, Schrader J. Bacteria-Free Gastrototoxic Helicobacter Pylori Filtrates: An Experimental Study. (Abstract) Modern Pathol 5(1): A274, 1992.
31. del Rosario AD, Bui HX, Khan M, Abdulla M, Pastore J, Ross JS. Prostatic Intraluminal "Crystalloids": Significance as an Indicator of Prostatic Malignancy. (Abstract) Modern Pathol 5(1): A299, 1992.
32. Bui HX, Ballouk F, Abdulla M, del Rosario AD, Khan M, Jennings TA, Ross JS. Nuclear DNA Content and Clinical Follow Up in Resected Pancreatic Adenocarcinoma. (Abstract) Modern Pathol 5(1): A562, 1992.
33. Khan M, Bui HX, Abdulla M, del Rosario AD, Ballouk F, Sim YJ, Ross JS. Role of DNA Content Determination by Image Analysis in Confirmation of Dysplasia in Barrett's Esophagus. (Abstract) Modern Pathol 5(1):A250, 1992.
34. Abdulla M, Bui HX, Khan M, del Rosario AD, Wolf BC, Ross JS. Angiomyolipomas: DNA Content and Immunohistochemical Study of Classic and Giant Multicentric "Malignant" Variants. (Abstract) Modern Pathol 5(1):A2, 1992.
35. Nazeer T, Church K, Amato C, Rosano T, Malfetano J, Ross JS. Cathepsin D Quantitation by Image Analysis in Endothelial Adenocarcinoma: Predictor of Tumor Aggressiveness. (Abstract) Lab Invest 66(1):67A, 1992.
36. Ross JS, Bakst G, Weisheit D, Solis OG, Figge J. Variable Expression of Retinoblastoma Protein in Human Thyroid Neoplasms. (Abstract) Lab Invest 66(1):38A, 1992.
37. Bui HX, del Rosario AD, Abdulla M, Ballouk F, Bajakian V, Lee CY, Ross JS. Ultrastructural study of experimental duodenal ulcer in a new animal model. Presented at the 50th Annual Meeting of the Electron Microscopy Society of America, Boston, 1992.
38. Bui HX, del Rosario AD, Abdulla M, Sheehan CE, Emerson RJ, Singh J, Ross JS. Electron microscopic and electron probe x-ray microanalysis (EPXMA) of prostatic intraluminal "crystalloids". Presented at the 50th Annual Meeting of the Electron Microscopy Society of America, Boston, 1992.
39. Ballouk F, Solis OG, Malfetano J, Bui HX, Ross JS. Prospective correlation of image analysis determination of DNA content of endometrial adenocarcinoma with standard prognostic factors. Presented at the 1992 Fall Meeting of the ASCP/CAP, Las Vegas, 1992. Am J Clin Pathol 98(3):352A, 1992.

40. del Rosario AD, Bui HX, Veloso JD, Abdulla M, Khan M, Ambros RA, Solis OG, JS Ross. DNA content and tumor proliferative activity (TPA) of adult-type ovarian granulosa cell tumors (GCT) by image analysis. Presented at the 1992 Fall Meeting of the ASCP/CAP, Las Vegas, 1992. *Am J Clin Pathol* 98(3):353A, 1992
41. Bui HX, Jennings TA, Sheehan CE, Abdulla M, del Rosario AD, Emerson RJ, Singh J, Ross JS. Silicone identification in soft tissue by electron probe x-ray microanalysis (EPXMA). Presented at the 1992 Fall Meeting of the ASCP/CAP, Las Vegas, 1992. *Am J Clin Pathol* 98(3):377A, 1992.
42. Bui HX, del Rosario AD, Abdulla M, Ross JS. The effect of hot pepper on gastric mucosa: Capsaicin delays healing of experimental gastric ulcers. *Modern Pathology* 6(1): 43A, 1993.
43. Ross JS, Bui HX, del Rosario AD, Venezia R, Schrader J, George M, Malamood H. Rapid serologic diagnosis of *Helicobacter pylori* associated gastritis: Comparison with gastroscopic findings. *Modern Pathology* 6(1), 1993.
44. Ballouk F, Bui HX, del Rosario AD, Chhieng C, Ross JS. Prediction of prognosis in cartilaginous neoplasms of bone by DNA ploidy analysis. *Modern Pathology* 6(1): 4A, 1993.
45. del Rosario AD, Bui HX, Ross JS. Comparative evaluation of special stains in the detection of early myocardial ischemic injury. *Modern Pathology* 6(1): 22A, 1993.
46. Ballouk F, Bui HX, del Rosario AD, Jennings TA, Ginsburg R, Ross JS. Comparison of DNA content with classic predictors of prognosis in esophageal squamous cancer. *Modern Pathology* 6(1): 43A, 1993.
47. Bui HX, del Rosario AD, Ballouk F, Jennings TA, Boguniewicz A, Sheehan C, Singh J, Ross JS. Reaction to silicone breast implants: Morphologic, immunofluorescent, and electron probe x-ray microanalytic (EPXMA) Findings. *Modern Pathology* 6(1): 12A, 1993.
48. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HAG. Contribution of Her-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. *Modern Pathology* 6(1): 68A, 1993.
49. Kallakury BVS, Figge JJ, Ross JS, Fisher HAG, Figge HL, Jennings TA. Correlation of p53 immunoreactivity with tumor grade in prostatic carcinoma. (Abstract) *Am J Clin Pathol* 100(3):319, 1993.
50. del Rosario AD, Bui HX, Wu A-YS, Ross JS. Selective binding of lectins to prostatic adenocarcinoma. (Abstract) *Am J Clin Pathol* 100(3):320, 1993.
51. Ross JS, Figge HL, Ross MS. Impact of instrumentation on DNA content determination by image analysis comparison of the cell analysis systems CAS 200 with Roche pathology workstation RPW. (Abstract) *Am J Clin Pathol* 100(3):345, 1993.
52. Bui HX, Sheehan CE, Yang W, del Rosario AD, Singh J, Ross JS. Scanning electron microscopic and electron probe x-ray microanalysis of airborne particulates in comparable cities of the United States and People's Republic of China. (Abstract) *Am J Clin Pathol* 100(3):345, 1993.

53. BVS. Kallakury, R. Kelty, JS. Ross, K. Amyot. Prevalence, histological characteristics and clinical significance of meconium in placentas. Society for Pediatric Pathology, New Orleans, March 1993
54. Ma M, Chhieng C, Schwartz C, Mudzinski S, Amyot KM, Ross JS. DNA Ploidy Analysis of Partial Hydatidiform Mole by Microdensitometry vs Flow Cytometry. (Abstract) Am J Clin Pathol, 1994.
55. Ross, JS, Figge H, Bui HX, del Rosario AD, Fisher HAG, Rifkin M, Jennings TA. Prediction of Pathologic Stage and Post Prostatectomy Disease Recurrence by DNA Ploidy Analysis of Initial Prostatic Cancer Needle Biopsy Specimens. (Abstract) Lab Invest 70(1):81A, 1994.
56. del Rosario AD, Bui HX, Singh J, Petrocine S, Sheehan C, Ross JS. True Synovial Metaplasia of Breast Implant Capsules: A Light and Electron Microscopic Study. (Abstract) Lab Invest 70(1):14A, 1994.
57. del Rosario AD, Bui HX, Wu AS, Kim DN, Figge H, Fisher HAG, Sheehan C, Ross JS. CD 44 and E-Cadherin (EC) Expression in Transitional Cell Carcinoma of the Urinary Bladder (UB-TCC). (Abstract) Lab Invest 70(1):73A, 1994.
58. Ross JS, Figge H, Bui HX, del Rosario AD, Fisher HAG, Nazeer T, Jennings TA, Ingle R, Kim DN. E-Cadherin Expression in Normal Prostate and Prostatic Carcinoma. (Abstract) Lab Invest 70(1):81A, 1994.
59. Bui HX, del Rosario AD, Bui LX, Ross JS. The Effects of Monosodium Glutamate (MSG) on Intact and Ulcerated Gastric Mucosa in an Experimental Animal Model. (Abstract) 57A, 1994.
60. Kallakury B, Figge J, Jennings T, Ross JS. Is P53 Mutation in Prostatic Adenocarcinoma (PAC) an Early Event? An Analysis by Microdissection and Molecular Techniques. (Abstract) Lab Invest 70(1):78A, 1994.
61. Ross JS, Bui HX, del Rosario AD, Sanderson B. Selective Expression of Cell Adhesion Marker CD 44 in Fine Needle Aspiration Biopsies of Thyroid Papillary Carcinoma. Accepted for presentation at the 42nd Annual Meeting of the American Society of Cytology, 1994.
62. Bui, H.X., del Rosario A.D., Chhieng C., Wu, A.-Y., Sheehan C., Singh J., Ross J.S. Melanosis Coli: A Clinical, Pathologic, Scanning Electron Microscopic (SEM) and Electron Probe X-Ray Microanalytic (EPXMA) Study. Accepted for presentation at the XX International Congress of the International Academy of Pathology & 11th World Congress of Academic and Environmental Pathology, Hong Kong, October 1994
63. Bui HX, del Rosario AD, Petrocine S, Singh J, Ginsburg R, Ross JS, Mihm MC. Intracytoplasmic Hyaline Globules of Kaposi's Sarcoma: Immunohistochemical, Ultrastructural and Electron Probe Microanalytic Features. Presented at the Fall ASCP/CAP National Meeting in Washington DC, October 1994.

64. Bui HX, del Rosario AD, Malaikkal b, Singh J, Sheehan C, Lee CY, Ingle R, Ross JS. Pathogenesis of Helicobacter Pylori- Associated Gastritis: Ultrastructural Markers. Presented at the Fall ASCP/CAP National Meeting in Washington DC, October 1994.
65. del Rosario AD, Bui HX, Abdulla M, Ross JS. Sulfur-rich Prostatic Intraluminal Crystalloids: A Surgical Pathologic and Electron Probe X-ray Microanalytic Study. *Advances in Anatomic Pathology*, 1(1), 58A, 1994.
66. Ross JS, Bui HX, del Rosario AD, Sanderson B, Sheehan C. Selective Expression of Cell Adhesion Marker CD44 in Fine Needle Aspiration Biopsies of Thyroid Papillary Carcinoma. *Acta Cytologica* 38(5):849, 1994 (abstract).
67. Rifkin MD, Ross JS, Figge HL, del Rosario AD, Jennings TA: Prediction of pathologic stage: DNA ploidy analysis and histologic grading using a comparison of ultrasound guided prostate needle biopsy and radical prostatectomy specimens. *Radiology*; 193(P):315; 1994.
- 68 Ross JS, Eastman A, Mastrangelo A, Baker JE, Kim DN. Effects of non-steroidal antiinflammatory drugs on monocyte-endothelial cell interaction. *Annals of the New York Academy of Sciences* volume 748:559; (abstract) 1995.
69. Chhieng C, Boguniewicz A, Ross JS. Differentiation of Reactive Atypia from Recurrent Transitional Cell Carcinoma by Image Analysis Determination of DNA Ploidy on Urothelial Cytology Specimens from Patients Treated with Intravesicle Chemotherapy. (Abstract) *Lab Invest* 72(1): 38A, 1995.
70. Ross JS, Chhieng C, Sheehan C. E-Cadherin Cell Adhesion Molecule Expression As A Diagnostic Adjunct in Urothelial Cytology. (Abstract) *Lab Invest* 72(1): 43A, 1995.
71. del Rosario AD, Kallakury BVS, Figge J, Bui HX, Ross JS. Selective Expression of Cell Adhesion Molecule CD44 in Thyroid Papillary Carcinoma. (Abstract) *Lab Invest* 72(1): 52A, 1995.
72. Figge J, Gerasimov G, Bronstein M, Jennings TA, Troshina K, Kallakury BVS, Izquierdo R, Alexandrova G, Dedov I, Boguniewicz AB, Figge HL, Robinson L, Ross JS. Increased Levels of the P53 Tumor Suppressor Gene Product in Differentiated Papillary Thyroid Cancers from Moscow, Russia: A Comparison with Cases from Albany, New York. (Abstract) *Lab Invest* 72(1): 53A, 1995.
72. Scalzo D, del Rosario AD, Bui HX, Singh JK, Ross JS. Overexpression of *BCL-2* Protein in Papillary Carcinomas of the Thyroid Gland. (Abstract) *Lab Invest* 72(1): 56A, 1995.
74. Bui HX, del Rosario AD, Chhieng DC, McKenna BJ, Wu AY, Ross JS. Role of DNA Content Analysis in the Differential Diagnosis of Cellular Atypia in Small Gastric Ulcer Endoscopic Biopsies. (Abstract) *Lab Invest* 72(1): 58A, 1995.
75. Chhieng DC, Okby N, Bui HX, del Rosario AD, Porter K, Wu AY, Ross JS. Expression of 1.25 Dihydroxyvitamin D3 Receptor (VDR) in Colonic Adenomas and Adenocarcinomas. (Abstract) *Lab Invest* 72(1): 59A, 1995.

76. Ingle R, Ross JS, McKenna BJ. BCL-2 Expression in Barrett Esophagus Associated Dysplasia and Adenocarcinoma. (Abstract) Lab Invest 72(1): 63A, 1995.
77. Daas M, del Rosario AD, Bui HX, Singh K, Ross JS. BCL-2 Protein Expression Is Related to Cellular Differentiation in Urinary Bladder Transitional Cell Carcinoma (UB-TCC). (Abstract) Lab Invest 72(1); 74A, 1995.
78. Hou J, Kallakury B, Bui HX, del Rosario AD, Figge H, Dao TD, Wu AY, Ginsburg R, Ross JS. Multivariate Analysis of Prognostic Factors in Pure Testicular Seminoma. (Abstract) Lab Invest 72(1): 77A, 1995.
79. Kallakury BVS, Figge J, Leibovich B, Rifkin M, Kaufman R, Figge HL, Nazeer T, Ross JS. Increased BCL-2 Protein Levels in Prostatic Adenocarcinomas Are Not Associated with Rearrangements in the 2.8 KB Major Breakpoint Region or with P53 Protein Accumulation. (Abstract) Lab Invest 72(1): 78A, 1995.
80. Okby N, del Rosario AD, Bui HX, Sheehan C, Porter K, Singh JK, Ross JS. Cartilage-Link Ligand of CD44 Cell Adhesion Molecule Expression in Urinary Bladder Transitional Cell Carcinoma (UB-TCC). (Abstract) Lab Invest 72(1): 81A, 1995.
81. Ross JS, Nazeer T, Figge HL, Fisher HAG, Rifkin MD. Cathepsin D Levels in Prostatic Carcinoma Biopsies by Quantitative Immunohistochemistry. (Abstract) Lab Invest 72(1): 82A, 1995.
82. Chhieng DC, Ross JS, Ambros RA. BCL-2 Expression and the Development of Endometrial Carcinoma. (Abstract) Lab Invest 72(1): 87a, 1995.
83. Kallakury BVS, Ambros RA, Ross JS, Malfetano JH, Kim Y, Hwang J, Figge J. P53 Gene Status in Endometrial Carcinomas Showing Diffuse Positivity for P53 Protein by Immunohistochemistry (IMH). (Abstract) Lab Invest 72(1): 91A, 1995.
84. Bui HX, del Rosario AD, Chhieng C, Wu AS, Sheehan C, Malaikkal B, Singh J, Ross JS. Melanosis Coli: A Clinical Pathologic, Scanning Electron Microscopic (SEM) and Electron-Probe X-ray Microanalytic (EPXMA) Study. (Abstract) Int J Surg Pathol 1995; 2 (suppl): 155.
85. Tran TA, Kallakury BVS, Sheehan C, Ross JS. Co-expression of Transforming Growth Factor-Alpha and Transforming Growth Factor-Beta in Non-Small Cell Lung Carcinomas. (Abstract) Modern Pathol 9(1):956, 1996.
86. Tran TA, Kallakury BVS, Ross JS. Expression of CD44 Standard Form and Variant Isoforms in Non-Small Cell Lung Carcinomas. (Abstract) Modern Pathol 9(1):957, 1996.
87. Bui HX, del Rosario AD, Dao TD, Venezia RA, Troutt A, Ross JS. Tumor Necrosis Factor Receptor FC Fusion Protein (TNFR:Fc) Promotes Healing of Helicobacter Pylori (HP)-Exposed Experimental Gastric Ulcers. (Abstract) Modern Pathol 9(1):838, 1996.
88. Wharton JM, Chhieng DC, Hou J, del Rosario AD, Sheehan CE, Ross JS. Expression of Transforming Growth Factor Beta, Transforming Growth Factor -Alpha and Epidermal Growth Receptor in Renal Cell Carcinoma. (Abstract) Modern Pathol 9(1):491, 1996.

89. Nazeer T, Ro JY, Tormos C, Ordonez NG, Ross JS, Ayala AG. Endocervicosis of the Urinary Bladder: A Clinical Pathologis Study of Six Cases. (Abstract) Modern Pathol 9(1):452, 1996.
90. Kallakury BVS, Figge J, Yang F, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG, Kaufman R, Figge H, Ross JS. Down-Regulation of CD44 Protein and mRNA in Prostate Cancer. Correlation with Tumor Grade and Ploidy. (Abstract) Modern Pathol 9(1):430, 1996.
91. Bui HX, del Rosario AD, Bui LX, Venezia RA, Troutt A, Ross JS. Effects of Interleukin-15 (IL-15) on the Healing of Helicobacter Pylori (HP)-Exposed Experimental Gastric Ulcers. (Abstract) Modern Pathol 9(1):307, 1996.
92. Hou J, Kusior MF, del Rosario AD, Bui HX, Pastore J, Wu AS, Singh JK, Ross JS. Cathepsin D (CD) Expression in Papillary Thyroid Carcinomas (PTC) Predicts Lymph Nodal Metastasis. (Abstract) Modern Pathol 9(1):268, 1996.
93. McKenna BJ, Chhieng DC, Ilves R, Figge HL, Ross JS. DNA Ploidy Determination by Image Analysis of Monolayer Smears Prepared from Mucosal Brushing Specimens. (Abstract) Modern Pathol 9(1):191, 1996.
94. Chhieng DC, Ross JS, McKenna BJ. CD44 Immunostaining of Thyroid Fine Needle Aspirates Differentiates Thyroid Papillary Carcinoma from Other Lesions with Nuclear Grooves and Inclusions. (Abstract) Modern Pathol 9(1):173, 1996.
95. Ross JS, Sheehan CE, Hayner-Buchan, Ambros RA, Kallakury BVS, Kaufman RA, Fisher HAG, Muraca PJ. HER-2/*neu* Gene Amplification Status in Prostatic Cancer (PC) by Fluorescence In-situ Hybridization (FISH). Am J Hum Genet 59: a80, 1996.
96. Bajas M, Rifkin MD, Vo T, Cheng S, Czerwskvj C, Ross JS. Should PSA or PSA density be used as the determining factor when deciding which prostate to biopsy during prostate ultrasound? Radiology 201:254, 1996.
97. Purdy S, Brien T, Ilves R, Ross JS, McKenna BJ. Bronchioalveolar Carcinoma in childhood associated with congenital cystic adenomatoid (CCAM). (Abstract) Modern Pathol 10(1):170A, 1997.
98. Riben MW, Sheehan CE, Malfetano JH, T Nazeer T, Ambros RA, Ross JS. Determination of HER-2/*neu* amplification (AMP) by fluorescence in-situ hybridization (FISH) in endometrial carcinoma (EC): Prognostic valuae compared to other pathologis features (Abstract) Modern Pathol 10(1):108A, 1997.
99. Okby N, Tran T, Kallakury BVS, Sheehan CE, Ross JS. Demonstration of HER-2/*neu* gene amplification in non small cell lung carcinomas using tissue fluorescence in-situ hybridization (FISH) . (Abstract) Modern Pathol 10(1):169A, 1997.
100. Hou J, Nazeer T, Sheehan CE, del Rosario A, Ross JS. HER-2/*neu* amplification (AMP) by fluorescence in-situ hybridization (FISH) in testicular germ cell tumors. (Abstract) Modern Pathol 10(1):77A, 1997.

101. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, R Kaufman, Fisher HAG, Muraca PJ. HER-2/*neu* gene amplification status in prostatic cancer (PC) by fluorescence in-situ hybridization. (Abstract) Modern Pathol 10(1): 87A, 1997.
102. Ingle R, Jennings TA, Goodman ML, Pilch BZ, Bergman S, Ross JS. CD44 expression in sinonasal inverted papillomas (SIP) and associated squamous cell carcinoma (SCC). (Abstract) Modern Pathol 10(1):115A, 1997.
103. del Rosario AD, Hou J, Sheehan CE, Petrocine S, Singh JK, Ross JS. Computer assisted image analysis of DNA ploidy, proliferation index and microvessel density of papillary thyroid carcinoma. (Abstract) Modern Pathol 10(1):49A, 1997.
104. Tran TA, Nazeer T, Oharia NS, Ross JS. Correlation of morphologic features and apoptotic index with failure of combined endocrine therapy in prostatic adenocarcinoma (PC). (Abstract) Modern Pathol 10(1):92A, 1997.
105. Brien TP, McKenna BJ, Okby NT, Sheehan CE, Ross JS. N-MYC amplification by fluorescence in-situ hybridization (FISH) in small cell lung cancer (SCLC), atypical carcinoid (AC) and typical carcinoid (TC) tumors of the lung. (Abstract) Modern Pathol 10(1):161A, 1997.
106. Kallakury BVS, Sheehan CE, Ambros RA, Fisher HAG, Kaufman R, Ross JS. Prognostic significance of p34^{cdc2} cyclin dependent kinase and cyclin D1 protein expression in prostatic adenocarcinomas (PACs). (Abstract) Modern Pathol 10(1): 79A, 1997.
107. Kallakury BVS, Tran TA, Okby NT, Ross JS. Immunohistochemistry of p34^{cdc2} cyclin dependent kinase (CDK) and cyclin D1 in primary lung carcinomas (PLC). (Abstract) Modern Pathol 10(1):166A, 1997.
108. Scalzo D, Kallakury BVS, Gaddipati R, Sheehan CE, Keys HM, Savage D, Ross JS. Prognostic factors in post radiation recurrence (PRR) of prostatic adenocarcinomas (PACS). (Abstract) Modern Pathol 10(1):89A, 1997.
109. Hou J, del Rosario A, Wharton J, Sheehan C, Petrocine S, Ross JS. HER-2/*neu* gene amplification by fluorescence in-situ hybridization (FISH) in clear cell renal cell carcinoma. (Abstract) Modern Pathol 10(1):77A, 1997.
110. Brien TP, Kallakury BVS, Lowry CV, Ambros RA, Malfetano JH, Ross JS. Telomerase activity in benign endometrium (BE) and endometrial carcinoma (EC). (Abstract) Modern Pathol 10(1):97A, 1997.
111. Yang F, Kesack A, Ross JS, Ilves R, Moores DW, McKenna BJ. Detection of telomerase activity in malignant cytology. (Abstract) Modern Pathol 10(1): 40A, 1997.
112. Kallakury BVS, Brien TP, Lowry CV, Fisher HAG, Kaufman R, Rifkin MD, Ross JS. Telomerase activity in benign prostate tissue and prostatic adenocarcinomas (PACs). (Abstract) Modern Pathol 10(1):78A, 1997.

113. Tran TA, Kallakury BVS, Ambros RA, Ross JS. Prognostic significance of tumor necrosis factors (TNF) and their receptors (TNFR) in non small cell lung carcinoma (NSCLC). (Abstract) *Modern Pathol* 10(1):173A, 1997.
114. Carlson JA, Ambros RA, Malfetano JH, Ross JS, Grabowski R, Lamb P, Figge H, Mihm M. vulvar lichen sclerosis shows premalignant changes not apparent by light microscopy. (Abstract) *Modern Pathol* 10(1):97A, 1997.
115. Tran A, Jennings TA, Ross JS, Nazeer T. Pseudomyxoma ovarii-like post-therapeutic alteration in prostatic adenocarcinoma (PAC): A distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. (Abstract) *Modern Pathol* 10(1):92A, 1997.
116. Ross JS, Kallakury BVS, Sheehan CE, Muraca PJ, Ambros RA. HER-2/*neu* oncogene amplification and p34^{cdc2} cyclin dependent kinase overexpression predict recurrence in prostate cancer. Abstract accepted for presentation at the 1997 American Association of Cancer Research 88th Meeting in San Diego, CA April 1997.
117. Ross JS, Muraca PJ. Applications of fluorescence in-situ hybridization (FISH) in the diagnosis and prognosis assessment of solid tumors. Abstract accepted for presentation at the 14th International Conference on Human Tumor Markers in Jerusalem, Israel June 15-19, 1997; *Journal of Tumor Marker Oncology* 12(2):A70, pg 68, 1997.
118. Rifkin MD, Tublin ME, Cheruvu SK, Li S, Ross J. Ultrasound contrast enhanced color Doppler: Initial results in the evaluation of the prostate. *Radiology*; 205(P):280, 1998
119. Rifkin MD, King BF, Zagoria RJ, McCauley TR, Peters T, Ross J, et al. MR imaging in prostate cancer: A reassessment of its clinical value in conjunction with clinical data. *Radiology*; 205(P):151; 1997.
120. Rifkin MD, Li S, Peters T, Ross J. Prostate cancer biopsy tissue diagnosis: Is visual inspection an adjunct to ultrasound guidance? *Radiology*; 205(P):151; 1997.
121. Vo T, Rifkin MD, Czerwinskyj C, Bajas M, Cheng S, Ross JS. Should ultrasound criteria of prostate be redefined to better evaluate when and where to biopsy? Proceedings of the American Institute of Ultrasound in Medicine, 41 Annual Convention, 16; 3:20; 1997.
122. Vo T, Rifkin MD, Czerwinskyj C, Bajas M, Cheng S, Ross JS. Should ultrasound criteria of prostate be redefined to better evaluate when and where to biopsy? Proceedings of the American Roentgen Ray Society 97th Annual Meeting; 168(3):75; 1997.
123. Mu XC, Brien TP, Ross JS, Lowry CV, McKenna BJ. Telomerase activity in malignant cytologic fluids. *Modern Pathology* 11(1); 41A; 1998.
124. Ng BT, Ingle R, Brien TP, Purdy S, Sheehan CE, Ross JS, Nazeer T. Evaluation of paraffin reactive CD 5 antibody in chronic lymphocytic leukemia /small lymphocytic lymphoma. *Modern Pathology* 11(1); 137A; 1998.
125. Mu XC, Hou J, Nazeer T, Ross JS. Cell cycle regulators in primary renal cell carcinoma. *Modern Pathology* 11(1); 90A; 1998.

126. del Rosario AD, Ross JS. Stromal mast cell density in benign and malignant prostatic lesions. *Modern Pathology* 11(1); 80A; 1998.
127. Tran TA, Kallakury BVS, Ambros RA, Ross JS. Immunohistochemical expression of the transforming growth factor Beta 1 correlates with long term survival in non small cell lung carcinoma. *Modern Pathology* 11(1); 180A; 1998.
128. Kallakury BVS, Sheehan CE, Rhee SJ, Fisher HAG, Kaufman, Jr. RP, Rifkin MD, Ross JS. Prognostic significance of cell cycle regulatory proteins (cyclins A and B) and proliferation associated antigens (p120, Ki-67, and PCNA) in prostatic adenocarcinomas. *Modern Pathology* 11(1); 86A; 1998.
129. Yang F, Ambros RA, Kallakury BVS, Sheehan CE, Malfetano JH, Muraca PJ, Ross JS. HER-2/neu oncogene amplification by fluorescence in-situ hybridization in ovarian neoplasms. *Modern Pathology* 11(1); 117A; 1998.
130. Depowski PL, Brien TP, Sheehan CE, Muraca PJ, Stylos S, Johnson RL, Ross JS. HER-2/neu oncogene amplification in breast cancer. *Modern Pathology* 11(1); 18A; 1998.
131. Tran TA, Carlson JA, Sheehan CE, Ross JS. Cell cycle antigen expression in melanocytic lesions. *Modern Pathology* 11(1); 54A; 1998.
132. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. *Modern Pathology* 11(1); 61A; 1998.
133. Hou J, del Rosario AD, Sim Y, Miller D, Pastore J, Singh J, Ross JS. Cathepsin D is overexpressed in clear cell renal cell carcinoma exhibiting solid growth pattern. *Modern Pathology* 11(1); 85A; 1998.
134. Graber, MW, Hayner-Buchanan A, Sheehan CE, del Rosario AD, Fisher HAG, Muraca PJ, Ross JS. HER-2/neu gene amplification and expression of cell cycle regulatory proteins in transitional cell carcinoma of the urinary bladder. *Modern Pathology* 11(1); 83A; 1998.
135. Williams SS, Tran TA, Sheehan CE, Ross JS. Cell proliferation markers as prognostic indicators in non-small cell lung cancer. *Modern Pathology* 11(1); 181A; 1998.
136. Hou J, del Rosario AD, Wharton J, Pastore J, Wu AS, Ross JS. Microvessel density correlates with aneuploidy in clear cell renal cell carcinoma. *Modern Pathology* 11(1); 85A; 1998.
137. Hayner-Buchanan A, Kallakury BVS, Sheehan CE, Malfetano JH, Ambros RA, Ross JS. Profile of cell proliferation associated proteins in endometrial carcinomas including Pap serous, endometrioid and villoglandular subtypes. *Modern Pathology* 11(1); 104A; 1998.
138. Ross JS, Muraca PJ, Jaffe D, Morgan T, Fletcher JA. Multivariate analysis of prognostic factors in lymph node negative breast cancer. *Modern Pathology* 11(1); 26A; 1998.
139. Ross JS, Ambros RA, Sheehan CE, Nazeer T, Jennings TA, Kallakury BVS. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. *Modern Pathology* 11(1); 93A; 1998.

140. Tran TA, Ayala AG, Amin MB, Nazeer T, Ro JY, Ross JS, Jennings TA. Utility of basal cell stain (34 Beta E12) in atypical small acinar proliferations in prostatic needle biopsies. *Modern Pathology* 11(1); 97A; 1998.
141. Boguniewicz AB, Hayner-Buchan A, Sanderson B, Ross JS. Immunocytochemical determination of estrogen and progesterone receptor protein in breast cancer specimens processed by the Cytoc Thinprep technique. *Modern Pathology* 11(1); 184A; 1998.
142. Hayner-Buchan A, Kallakury BVS, Gaddipati R, Keys HM, Rifkin MD, Sheehan CE, Ambros RA, Ross JS. Predictors of prostate cancer recurrence in patients receiving primary radiation therapy. *Modern Pathology* 11(1); 84A; 1998.
143. Harbeck N, Ross J, Dettmar P, Yurdseven S, Berger U, Hofler H, Graeff H, Schmitt M. HER-2/*neu* gene amplification determined by fluorescence in-situ hybridization (FISH) for risk-group assessment in node-negative breast cancer. *Breast Cancer Research and Treatment*, 307 (abstract), 1998.
144. del Rosario AD, Tran A, Kleabonas M, Singh JK, Ross JS. Ultrastructural features of prostatic adenocarcinoma induced by combination endocrine therapy. *Modern Pathology* 12(1); 93A; 1999.
145. Brinker DA, Ross JS, Tran TA, Jones DM, Epstein JI. Can ploidy of prostate cancer on needle biopsy predict radical prostatectomy stage and grade? *Modern Pathology* 12(1); 91A; 1999.
146. Ross JS, Sheehan CE, Abrahams HM, Fisher HAG, Kaufman, Jr RP, Rifkin MD, Kallakury BVS. Decreased expression of e-cadherin and catenin complex proteins in prostatic adenocarcinomas. *Modern Pathology* 12(1); 105A; 1999.
147. Sheehan CE, Chang T, Kallakury BVS, Croce C, Dincer A, Fisher HAG, Kaufman, Jr RP, Rifkin MD, Ross JS. FHIT tumor suppressor protein expression in prostate cancer. *Modern Pathology* 12(1); 107A; 1999.
148. Ross JS, Sheehan CE, Winn-Deen E, Oliver J, Kallakury BVS. E-cadherin expression loss in prostate cancer is associated with hypermethylation of the E-cadherin promoter gene and amplification of the HER-2/*neu* oncogene. *Modern Pathology* 12(1); 105A; 1999.
149. Riben MW, Kallakury BVS, Ambros RA, Sheehan CE, Malfetano JH, Hayner-Buchan A, Ross JS. Cell proliferation associated antigens and cell cycle regulatory proteins in ovarian epithelial tumors. *Modern Pathology* 12(1); 123A; 1999.
150. Hayner-Buchan A, Brein TP, Sheehan CE, Ross JS. HER-2/*neu* oncogene amplification determined by fluorescence in-situ hybridization is an independent predictor of survival in colorectal adenocarcinoma. *Modern Pathology* 12(1); 76A; 1999.
151. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Prognostic significance of topoisomerase II alpha expression in breast cancer. 1999.

152. Williams SS, Kren L, Tran TA, Sheehan CE, Ross JS. Expression of oncostatin M and topoisomerase II alpha in non-small cell lung carcinoma. 1999.
153. Graber MW, Abrahams HM, Sheehan CE, Fisher HAG, Kaufman, Jr RP, Ross JS. Prognostic significance of topoisomerase II alpha overexpression in transitional cell carcinoma of the urinary bladder. Modern Pathology 12(1); 96A; 1999.
154. Mu XC, Jones DM, Tran TA, Ross JS, Carlson JA. Expression of oncostatin M in benign and malignant melanocytic lesions. Modern Pathology 12(1); 61A; 1999.
155. Jones DM, Mu XC, Tran TA, Ross JS, Carlson JA. Expression of topoisomerase II alpha in benign and malignant melanocytic lesions. Modern Pathology 12(1); 58A; 1999.
156. Rosenthal SI, Depowski PL, Sheehan CE, Ross JS. HER-2/*neu* oncogene amplification detected by fluorescence in-situ hybridization in lobular breast cancer. Modern Pathology 12(1); 29A; 1999.
157. MW Graber, Abrahams HM, Sheehan CE, Fisher HAG, Kaufman, Jr RP, Ross JS. Clinical significance of HER-2/*neu* amplification and expression in transitional cell carcinoma of the urinary bladder. Modern Pathology 12(1); 96A; 1999.
158. Tran TA, Williams SS, Boehm JR, Ross JS, Carlson JA. Squamous cell carcinoma versus keratocanthoma: A study of mitotic cyclins and their dependent kinase. Modern Pathology 12(1); 64A; 1999.
159. Depowski PL, Rosenthal SI, Brien TP, Croce CM, Ross JS. Prognostic significance of FHIT protein expression in breast cancer. Modern Pathology 12(1); 19A; 1999.
160. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross, JS. HER-2/*neu* gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Modern Pathology 12(1); 72A; 1999.
161. Ross JS, Williams SS, Malfetano JH, Riben M, Ambros RA, Szyfelbein WM. CD44 standard form expression in ovarian neoplasms and benign ovarian epithelium. Modern Pathology 12(1); 123A; 1999.
162. Kronz JD, Silberman MA, Bastasky S, Burks RT, Cina SJ, Mills SE, Ross JS, Sakr WA, Tomaszewski JE, True LD, Ulbright TM, Weinstein MW, Yantiss RK, Young RH, Epstein JI. Pathology Residents using a web based tutorial improve Gleason Grading of Prostate Carcinoma in Needle Biopsies. 1999 United States and Canadian Academy of Pathology Platform and Posters March 20-26, 1999 San Francisco, CA.
163. Hayner-Buchan A, del Rosario AD, Sheehan CE, Ambros RA, Ross JS. Apoptotic index (AI) predicts survival in late stage colorectal cancer. Modern Pathology 13(1); 464A; 2000.
164. Graber MW, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman, Jr. RP, Ross JS. Expression of the c-kit receptor and its ligand stem cell factor in transitional cell carcinoma of the urinary bladder. Modern Pathology, 13(1); 578A; 2000.

165. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. *Modern Pathology* 13(1); 96A; 2000.
166. Nazeer T, Ross JS, Depowski PL. Interleukin-10 (IL-10) expression in large cell lymphoma predicts high tumor stage and short survival. *Modern Pathology*, 13(1); 927A; 2000.
167. Depowski PL, Nazeer T, Ross JS, Kallakury BVS. Expression of hepatocyte growth factor (HGF) protein in Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL): Correlation with prognostic variables. *Modern Pathology*, 13(1); 854A; 2000.
168. Hayner-Buchan A, del Rosario AD, Goncharuk VN, Ambros R, Sheehan CE, Ross JS. Fascin is overexpressed in high grade ovarian carcinomas. *Modern Pathology*, 13(1); 731A; 2000.
169. Williams SS, Pitman MB, Szyfelbein WM, Ross JS, Sheehan CE, McKenna BJ. Laminin immunostaining differentiates well-differentiated hepatocellular carcinoma from benign tissue in FNAB of liver. *Modern Pathology*, 13(1); 323A; 2000.
170. Williams SS, Pitman MB, Ross JS, Szyfelbein Wm, Sheehan CE, McKenna BJ. Computer-assisted image analysis in the diagnosis of hepatocellular carcinoma in fine needle aspiration biopsy. *Modern Pathology*, 13(1); 324A; 2000.
171. Brien TP, Depowski PL, McKenna BJ, Croce CM, Ross JS. FHIT protein expression in colon cancer using a novel antibody. *Modern Pathology*, 13(1); 439A; 2000.
172. Jones DM, Kren L, Sheehan CE, Ross JS, Boguniewicz AB. Geometric, densometric and texture morphometric features and DNA ploidy analysis in urothelial cytology specimens. *Modern Pathology*, 13(1); 193A; 2000.
173. Kallakury BVS, Nazeer T, Ross JS, Depowski PL. Immunohistochemical (IHC) expression of c-kit (CD117) and its ligand stem cell factor (SCF) in Hodgkin's (HL) and non-Hodgkin's lymphomas (NHL). *Modern Pathology*, 13(1); 893A; 2000.
174. Kallakury BVS, Sheehan CE, Boehm JR, Fisher HAG, Kaufman Jr. RP, Rifkin MD, Ross JS. Cell adhesion molecule interactions in prostatic adenocarcinomas (PACs): Correlation of CD44s downregulation and HER-2/*neu* amplification with e-cadherin/catenin protein expression. *Modern Pathology*, 13(1); 657A; 2000.
175. Dincer AD, Brien TP, Sheehan CE, McKenna BJ, Ross JS. Expression of c-kit and stem cell factor in human gastric adenocarcinomas. *Modern Pathology*, 13(1); 449A; 2000.
176. Nazeer T, Brien TP, Kallakury BVS, Ingle R, Lowry CV, Ross JS. Telomerase activity in Hodgkin's lymphoma (HL). *Modern Pathology*, 13(1); 928A; 2000.
177. del Rosario AD, Cerda J, Martinez D, Petrocine S, Ross JS. Hus-like renal complication caused by gemcitabine: Light and electron microscopic study. *Modern Pathology*, 13(1); 1339A; 2000.
178. Karikehalli S, Kallakury BVS, Sheehan CE, Bratslavsky G, Kaufman Jr. RP, Fisher HAG, Ross JS. Patterns of c-kit proto oncogene product expression in renal cell carcinoma:

Coexpression with stem cell factor (SCF) and correlation with high grade malignancy. *Modern Pathology*, 13(1); 659A; 2000.

179. Rosenthal SI, Depowski PL, Ross JS. Decreased expression of nm23-H1 is associated with increased recurrence of breast cancer. *Modern Pathology*, 13(1); 250A; 2000.

180. Rosenthal SI, Depowski PL, Ross JS. Decreased expression of KAI-1 protein in breast cancer. *Modern Pathology*, 13(1); 249A; 2000.

181. Depowski PL, Rosenthal SI, Ross JS. Evaluation of the prognostic significance of expression of c-kit and its ligand stem cell factor (SCF) in breast cancer. *Modern Pathology*, 13(1); 97A; 2000.

182. Karikehalli S, Kallakury BVS, Sheehan CE, Bratslavsky G, Kaufman JR. RP, Fisher HAG, Ross JS. Loss of expression of PTEN, nm23-H1 and KAI-1 tumor suppressor gene products in renal cell carcinomas (RCCs). *Modern Pathology*, 13(1); 660A; 2000.

183. Kaur P, Kallakury BVS, Sheehan CE, Strobe SA, Fisher HAG, Kaufman Jr. RP, Ross JS. Loss of expression of c-met gene product in human prostatic adenocarcinoma (PACs) correlates with high tumor grade and aneuploidy. *Modern Pathology*, 13(1); 661A; 2000.

184. Tran TA, Carlson JA, Sheehan CE, Ross JS. Apoptosis and transforming growth factor-Beta in squamous cell carcinoma and keratocanthoma. *Modern Pathology*, 13(1); 387A; 2000.

185. Goncharuk VN, del Rosario AD, Tran TA, Kallakury BVS, Sheehan CE, Ross JS. Co-downregulation of nm23-H1 and KAI-1 tumor suppressor proteins predicts adverse outcome in non-small cell lung cancer (NSCLC). *Modern Pathology*, 13(1); 1236; 2000.

186. Sachs B, Ledet E, Kelly A, Ross JS, Tran TA, King R, Sheehan CE, Tymeson M. Histopathology of tibial healing in dogs treated with the OP-1 implant. *Modern Pathology*, 13(1); 1183A; 2000.

187. Sheehan CE, Tran TA, Miller B, Kelly A, Sachs BL, Ledet E, Disler DG, Ross JS. Pathologic features of cervical spine fusion promoted by OP-1 putty. *Modern Pathology*, 13(1); 1184A; 2000.

188. Kren L, Goncharuk VN, del Rosario AD, Williams SS, Tran TA, Sheehan CE, Ross JS. Downregulation of β -catenin expression predicts shortened survival in non-small lung cancer. *Modern Pathology*, 13(1); 1249A; 2000.

189. Goncharuk VN, del Rosario AD, Tran TA, Kallakury BVS, Sheehan CE, Ross JS. Downregulation of PTEN gene product expression is an unfavorable prognostic indicator in non-small cell lung cancer (NSCLC). *Modern Pathology*, 13(1); 1235A; 2000.

190. Bhargava P, Kallakury BVS, Ross JS, Azumi N, Bagg A. CD79a is heterogeneously expressed in acute non-lymphoblastic leukemias (ANLL) and normal megakaryocytes and is antibody clone dependent. *Modern Pathology*, 13(1); 838A; 2000.

191. Kallakury BVS, Sheehan CE, Mu XC, Ross JS. Differential expression and variable prognostic significance of c-kit gene product (CD117) and its ligand stem cell factor (SCF) in human malignant neoplasms. American Association for Cancer Research Proceeding, 41;2098A; 331; 2000
192. Ross JS, Depowski PL, Sheehan CE, Rosenthal SI, Kallakury BVS. Co-expression of plasminogen activator inhibitor 1 (PAI-1), Urokinase (uPA), and urokinase receptor (uPAR) in mammary ductal carcinomas: Association of PAI-1 immunoreactivity with prognostic factors. Modern Pathology, 14(1); 186A, 2001.
193. Dincer AD, Xiong J, Ross JS, Sheehan CE, Williams SS, McKenna BJ. Cyclooxygenase-2 expression in human gastric gastroesophageal junction and esophageal adenocarcinomas. . Modern Pathology, 14(1); 480A, 2001.
194. Xiong J, Dincer AD, McKenna BJ, Sheehan CE, Ross JS. Survivin and bcl-2 are expressed differently in gastric and esophageal adenocarcinomas. . Modern Pathology, 14(1); 568A, 2001.
195. Anwar S, Jennings TA, Depowski PL, Ross JS, Nazeer T. Expression of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) in prostatic adenocarcinoma (PAC) correlates with tumor grade and stage. Modern Pathology, 14(1); 581A, 2001.
196. Graber MW, Kallakury BVS, Sheehan CE, Abrahams MH, Fisher HAG, Kaufman, Jr. RP, Ross JS. Expression of Transforming Growth Factor Beta-3 in Transitional Cell Carcinoma of the Urinary Bladder. Modern Pathology, 14(1); 634A, 2001.
197. Kallakury BVS, Karikehalli S, Hahol A, Sheehan CE, Azumi N, Ross JS. Co-expression of matrix metalloproteinase 2 and 9 and their inhibitor in renal cell carcinoma (RCC): Correlation with histologic and prognostic variables. Modern Pathology, 14(1); 649A, 2001.
198. Kallakury BVS, Abraham HM, Sheehan CE, Ross JS, Kogan B. Utility of CD99 (Anti MIC-2) in the histologic evaluation of undescended testes. Modern Pathology, 14(1); 650A, 2001.
199. Kallakury BVS, Sheehan CE, Lowry CV, Salmon SL, Anand RD, Fisher HAG, Kaufman Jr., RP, Ross JS. GST- π protein is downregulated in high grade PIN and prostatic adenocarcinomas (PACs): A preliminary analysis of association with methylation of the gene promoter. Modern Pathology, 14(1); 651A, 2001.
200. Karikehalli S, Hahol A, Sheehan CE, Azumi N, Ross JS, Kallakury BVS. Utility of c-kit immunoreactivity in the classification of renal cell carcinomas (RCCs): Differential expression of c-kit, RCC and CD10 proteins in chromophobe RCCs. Modern Pathology, 14(1); 655A, 2001.
201. Karikehalli S, Kallakury BVS, Sheehan CE, Azumi N, Fisher HAG, Kaufman, Jr., RP, Ross JS. Immunoreactivity for ubiquitin is an independent predictor of survival in renal cell carcinoma (RCC). Modern Pathology, 14(1); 656A, 2001.

202. Kaur P, Kallakury BVS, Sheehan CE, Smith K, Fisher HAG, Kaufman Jr., RP, Ross JS. Immunohistochemical expression of survivin and bcl-2 in prostatic adenocarcinomas (PACs). *Modern Pathology*, 14(1); 657A, 2001.
203. Ross JS, Kaur P, Smith K, Sheehan CE, Fisher HAG, Kaufman, Jr., RP, Kallakury BVS. Co-expression of matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinase 2 in prostatic adenocarcinomas (PACs). *Modern Pathology*, 14(1); 705A, 2001.
204. Mu XC, Ambros RA, Ross JS, Malfetano JH, Sheehan CE, Kallakury BVS. Expression of c-kit and stem cell factor (SCF) in primary ovarian neoplasms: Correlation of c-kit with carcinomas vs tumors of low malignant potential. *Modern Pathology*, 14(1); 825A, 2001.
205. Depowski PL, Graber MW, Purdy S, Ross JS, Nazeer T. Survivin expression predicts poor outcome in malignant lymphoma. *Modern Pathology*, 14(1); 941A, 2001.
206. Graber MW, Depowski PL, Purdy S, Ross JS, Nazeer T. Expression and significance of MUM1/IRF4 protein in Hodgkin's and non-Hodgkin's lymphoma. *Modern Pathology*, 14(1); 965A, 2001.
207. Jones DM, Depowski PL, Qian J, Graber MW, Ross JS, Nazeer T. Evaluation of inhibitors of apoptosis in primary CNS lymphoma. *Modern Pathology*, 14(1); 1226A, 2001.
208. del Rosario AD, Goncharuk VN, Tran TA, Sheehan CE, Ross JS. Fascin immunoreactivity correlates with tumor grade in non-small cell lung cancer (NSCLC). *Modern Pathology*, 14(1); 1283A, 2001.
209. Goncharuk VN, Kren L, Ross JS. Immunohistochemical expression of ubiquitin correlates with long term survival in non-small cell lung carcinoma (NSCLC). *Modern Pathology*, 14(1); 1293A, 2001.
210. Goncharuk VN, Kallakury BVS, Sheehan CE, Ross JS. Matrix metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase1 (TIMP1) as prognostic markers in non-small cell lung cancer (NSCLC). *Modern Pathology*, 14(1); 1294A, 2001.
211. Kren L, Goncharuk VN, Kallakury BVS, Sheehan CE, Ross JS. *Modern Pathology*, 14(1); 1307A, 2001.
212. Ross JS, Kallakury BVS, Sheehan CE, Salmon SL, Anand RD, Fisher HAG, Kaufman, Jr. RP, Lowry CV. Immunohistochemical downregulation of GST-pi protein and methylation of the gene promoter are associated with majority of prostatic adenocarcinomas (PACs). *Proceedings of the American Association for Cancer Research*, February 2001.
213. Ross JS, Xiong JJ, Xy H, Sheehan CE, Kallakury BVS. Co-Expression of Matrilysin (MMP 7) and Stromelysin (MMPs 3,10, and 11) Proteins and Prognostic Significance in Mammary Carcinomas. *Modern Pathology*, 15(1); 195, 2002.
214. Xiong JJ, Kallakury BVS, Sheehan CE, Ross JS. Heat Shock Protein 27, Estrogen Receptor Protein and Progesterone Receptor Protein Expression and Clinical Outcome in Breast Cancer. *Modern Pathology*, 15(1); 226, 2002.

215. Xiong JJ, Kallakury BVS, Sheehan CE, Ross JS. Co-Expression of Heat Shock Transcription Factor 1 with Heat Shock Protein Expression in Breast Cancer. *Modern Pathology* 15(1); 2002.
216. Goncharuk VN, Ross JS, Carlson JA. Actin-Binding Protein Fascin Expression Is Lost in the Progression of Malignant Skin Cancers. *Modern Pathology* 15(1); 406, 2002.
217. Anwar S, Jennings TA, Ross JS, Nazeer T. Central Zone Glands: A Potential source of Diagnostic Confusion with High Grade Prostatic Intraepithelial Neoplasia (HGPIN), *Modern Pathology* 15(1); 634, 2002.
218. Jennings TA, Murray BP, Ross JS, Fisher HAG, Sheehan CE, Lee E, Kallakury BVS. Rectal Ulceration and Associated Pseudomalignant Epithelial Changes after Prostate Seed Brachytherapy. *Modern Pathology* 15(1); 690, 2002.
219. Kallakury BVS, Sheehan CS, Fisher DA, Depowski PL, Ross JS, Jennings TA. Immunophenotypic Analysis of Renal and Adrenal Neoplasms: Utility of MiTF, Inhibin, Calretinin and CD10 in the Differential Diagnosis. *Modern Pathology* 15(1); 693, 2002.
220. Kallakury BVS, Weinman S, Sheehan CE, Glass AG, Williams MA, Young BA, Ross JS. Immunohistochemical Evaluation of Cell Cycle Regulators, Growth Factors and Cell Adhesion Proteins as Prognostic Indicators in Renal Cell Carcinomas (RCC). *Modern Pathology* 15(1); 694, 2002.
221. Xang XH, Sheehan CE, Ross JS, Qian J. Expression of Apoptosis-Related Molecules Survivin, BCL-2, Bax, Caspase-3 and p53 in CNS Schwannomas. *Modern Pathology* 15(1); 1260, 2002.
222. Goncharuk VN, Kren L, Anwar S, Sheehan CE, Smith I, Ross JS. Overexpression of MMP-7 (Matrilysin) Is an Unfavorable Prognostic Indicator in Non-Small Cell Lung Cancer (NSCLC). *Modern Pathology* 15(1); 1331, 2002.
223. Goncharuk VN, Kren L, Anwar S, Sheehan CE, Xiong JJ, Ross JS. Expression and Prognostic Significance of Cyclooxygenase-2 (COX-2) in Non-Small Cell Lung Carcinoma. *Modern Pathology* 15(1); 1332, 2002.
224. Kren L, Goncharuk VN, Krenova Z, Sheehan CE, Ross JS. Tumor Cell Expression of Matrix-Metalloproteinases 3, 10 and 11 (Stromelysins 1, 2 and 3) in Non-Small Cell Lung Cancer. *Modern Pathology* 15(1); 1344, 2002.
224. Ross JS, Sheehan CE, Karikehalli S, Azumi N, Kallakury BVS. Co-expression of matrix metalloproteinases (MMPs) and poor prognostic significance in renal cell carcinomas (RRCs). *American Association for Cancer Research Proceedings*. 43:1983; 2002.
225. Patel D, Krug LM, Crapazano J, Pizzo B, Tyson L, Azzoli CG, Helan RT, Ventratkaman E, Ross JS, Sheehan C, Gomez J, Kris MJ, Miller VA. Clinical characteristics and outcomes of patients with advanced non-small cell lung cancer treated with trastuzumab plus either weekly docetaxel or paclitaxel. *Proceedings ASCO* 2002; 21:305A

226. Ross JS, Gray K, Mosher R, Deeds J, Fisher HAG, Kaur P, Sheehan CE, Kallakury BVS. Prostate specific antigen membrane (PSMA): Target validation and prognostic significance in prostate cancer. *Modern Pathology* 16; 167A, 2003.
227. Anwar S, Ambros RA, Jennings TA, Ross JS, Mian B, Nazeer T. Expression of CPP32/Caspase-3 in prostate adenocarcinoma correlates with tumor grade. *Modern Pathology* 16; 140A, 2003.
228. Kaur P, Kallakury BVS, Sheehan CE, Ross JS. Expression of NFkB pathway proteins in prostate cancer and correlation with clinical outcomes. *Modern Pathology* 16; 156A, 2003.
229. Nazeer T, Anwar S, Jennings TA, Ross JS, Mian B. Impact of extended biopsy schemes on prostatic adenocarcinoma detection in repeat biopsy specimens. *Modern Pathology* 16; 163A, 2003.
230. Xiong JJ, Sheehan CE, Xu H, Ambros RA, Ross JS. Expression of maspin and p53 in the histologic subtypes of endometrial carcinoma and in uterine mixed mesodermal tumors. *Modern Pathology* 16; 214A, 2003.
231. Mecca P, Xiong JJ, Sheehan CE, Boguniewicz AB, Ross JS. Expression of maspin protein in breast carcinoma and correlation with clinical outcome. *Modern Pathology* 16; 41A, 2003.
232. Xiong JJ, Mecca P, Depowski PL, Sheehan CE, Boguniewicz AB, Ross JS. Expression of survivin, bax and caspase proteins in breast carcinoma and correlation with clinical outcomes. *Modern Pathology* 16; 51A, 2003.
233. Xiong JJ, Mercurio JW, Sheehan CE, Petrocine S, Ambros RA, Ross JS. MMP-3, MMP-7, MMP-9 expression in endometrial carcinoma. *Modern Pathology* 16; 214A, 2003.
234. Ali AJ, Xiong JJ, Sheehan CE, Xu H, Ambros RA, Ross JS. Alteration of bax and p53 expression in the histologic subtypes of endometrial carcinomas and uterine malignant mixed mesodermal; tumors. *Modern Pathology* 16; 179A, 2003.
235. Ali AJ, Sheehan CE, Xiong JJ, Ross JS, Ambros RA. P27 expression in the development and behavior of epithelial ovarian tumors. *Modern Pathology* 16; 179A, 2003.
236. Kallakury BVS, Karikehalli S, Sheehan CE, Azumi N, Ross JS. Increased expression of matrilysin (MMP7) and stromelysin (MMP3, MMP 10, MMP 11) proteins as predictors of survival in RCCs. *Modern Pathology* 16; 155A, 2003.
237. Kallakury BVS, Karikehalli S, Sheehan CE, Rassaei N, Azumi N, Ross JS. Immunohistochemical expression of NFkB and Ikb proteins in renal cell carcinoma (RCC). *Modern Pathology* 16; 156A, 2003.
238. Kallakury BVS, Sheehan CE, Karikehalli S, Kaur P, Rassaei N, Azumi N, Ross JS. p27 mediated cell cycle regulation appears independent of skp2 expression in prostate and renal cancers. *Modern Pathology* 16; 156A, 2003.

239. Kaur P, Nazeer T, Ross JS, Sheehan CE, Jennings TA. Utility of immunohistochemistry in distinguishing invasive adenocarcinoma from misplaced epithelium in colonic adenomas. *Modern Pathology* 16; 124A, 2003.
240. Jennings TA, Sheehan CE, Stringer B, Sadis S, Brownell J, Reed M, Ross JS. p27 and SKP2 expression in non-small cell lung cancers (NSCLC). *Modern Pathology* 16; 3081A, 2003.
241. Karikehalli S, Kallakury BVS, Sheehan CE, Azumi N, Kaufman, Jr., RP, Fisher HAG, Ross JS. Expression of anti-apoptotic proteins surviving and bcl-2 in renal cell carcinoma (RCC). *Modern Pathology* 16; 138A, 2003.
242. Lavezzi W, Vincenti DM, Li Q, Sheehan CE, Ross JS, Qian J. Expression of nuclear factor-kB (NF-kB), IκBa and low affinity NGF receptor p75 in CNS schwannomas. *Modern Pathology* 16; 291A, 2003.
243. Li Q, Lavezzi WA, Vincenti DM, Sheehan CE, Ross JS, Carlson JA. SKP2 and p27 are inversely related in melanoma. *Modern Pathology* 16; 94A, 2003.
244. Vincenti DM, Li Q, Lavezzi WA, Sheehan CE, Ross JS, Qian J. Expression of nuclear factor kB (NFkB) and IκBa in meningiomas. *Modern Pathology* 16; 293A, 2003.
245. Gray KD, Mosher R, Bheddah S, Carpino A, Deeds J, Sheehan C, Kallakury BVS, Ross JS. Prostate specific membrane antigen (PSMA): target validation and prognostic significance in prostate cancer (PCA). *Proceedings of the AACR 44(170)*; 2003.
246. Stringer B, Galbraith S, Brownell J, Read M, Jennings TA, Sheehan CE, Ross JS. P27 and SKP2 expression in non-small cell lung cancers (NSCLC). *Proceedings of the AACR 44(1539)*; 2003.
247. Ross JS, Kallakury BVS, Sheehan CE, Karikehalli S, Kaur P, Mosher R, Badola S, Gray K. NFkB and IκBA protein expression in prostatic and renal carcinomas: correlation with disease outcome. *Proceedings of the AACR 44(5376)*; 2003.
248. Mulligan G, Bryant B, Stec J, Kim S, Morrissey M, Damokosh A, Singh A, Bolt A, Schmitt A, Metivier J, Larsen-Gallup J, Esseltine D, Adams J, Schenkein D, Boral A, Brown J, Linette G, Ross JS. Pharmacogenomic studies of bortezomib (VELCADE™) treatment in late stage multiple myeloma. *Hematol J* 4:S253; 2003.
249. Pusztai L, Ayers M, Symmans WF, Metivier J, Damokosh A, Clark, E, Sneige N, Valero, V, Hess K, Hortobagyi GN, Ross J, Stec J. Prospective Validation of Gene Expression Profiling based Prediction of Complete Pathologic Response to Neoadjuvant Taxol/FAC Chemotherapy in Breast Cancer. *Proceed ASCO (abstract)* 2003
250. Anwar S, Ambros RA, Jennings TA, Nazeer H, Mian B, Ross JS. Expression of syndecan-1/CD138 in prostatic adenocarcinoma (PAC) correlates with tumor Gleason score and pathological stage. *Modern Pathology* 17; 138A, 2004.
251. Anwar S, Zisman L, Canver C, Nazeer T, Ross JS, Hussain S, Nair K, Jennings TA. Hypersensitivity carditis in explanted hearts. *Modern Pathology* 17; 55A, 2004.

252. Anwar S, Mecca P, Wilson VL, Rohwedder A, Sheehan CE, Ross JS, Carlson JA. G1-S cell-cycle regulators in vulvar squamous cell carcinoma and precursor lesions. *Modern Pathology* 17; 189A, 2004.
253. Jennings TA, Alexander-Decker C, Gianoukakis A, Leinung M, Dobrzynski R. Effect of nodule size on the false negative rate of thyroid aspiration biopsy. *Modern Pathology* 17; 71A, 2004.
254. Kallakury BVS, Zhang L, Kaur P, Owor G, Sheehan CE, Kim S, Yang S, Ross JS, Jennings TA. Immunohistochemical (IHC) expression of the decoy receptor for FAS ligand (DcR3/TR6) correlates with grade and stage in colorectal adenocarcinomas (CRCs). *Modern Pathology* 17; 119A, 2004.
255. Kallakury BVS, Luka J, Sheehan CE, Kaur P, Ross JS, Appella E, Demidov ON, Azumi N, Hartmann DP. Immunohistochemical expression of the PPM1D/wip-1 protein in prostate adenocarcinoma (PAC). *Modern Pathology* 17; 161A, 2004.
256. Kaur P, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman, Jr. RP, Ross JS. Expression of heat shock proteins in prostate carcinoma. *Modern Pathology* 17; 161A-162A, 2004.
257. Kaur P, Kallakury BVS, Sheehan CE, Azumi N, Ross JS, Hayner-Buchan A. Loss of CD138 expression correlates with aggressive phenotype in clear cell renal cell carcinomas (RCCs). *Modern Pathology* 17; 161A, 2004.
258. Lavezzi WA, Vincenti DM, Sheehan CE, Ross JS, Qian J. Expression of matrix metalloproteinases MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in primary central nervous system lymphomas (PCNSLs). *Modern Pathology* 17; 318A, 2004.
259. Mecca P, Hutchinson KR, Wilson VI, Rohwedder A, Sheehan CE, Ross JS, Carlson JA. P16 methylation status and expression and HPV16 in vulvar squamous cell carcinoma and adjacent skin. *Modern Pathology* 17; 206A, 2004.
260. Nazeer T, Jennings TA, Anwar S, Ross JS, Mian B. Impact of extended prostate biopsy scheme on prediction of Gleason score in prostatectomy specimens. Accepted for platform presentation. *Modern Pathology* 17; 169A, 2004.
261. Nazir TM, Ross JS, Li Q, DeJulio A, Sheehan C, Mihm, Jr MC, Linette G, Carlson JA. Melastatin expression determined by a chromogenic in situ hybridization method (cish) in primary and metastatic melanoma. *Modern Pathology* 17; 97A, 2004.
262. Owor G, Nazeer T, Ginsburg R, Desmukh P, Pastore J, Baltch A. Splenic pathplogy in pseudomonas sepsis (PS). An autopsy study of 24 cases. *Modern Pathology* 17; 7A, 2004.
263. Owor G, Yang HX, Sheehan CE, Ross JS, Qian J. Expression of cytokeratin-7 (CK7), cytokeratin-20 (CK20), gross cystic disease fluid protein-15 (GCDFP-15), thyroid transcription factor-1 (TTF-1) and thyroglobulin in choroids plexus and its tumors. *Modern Pathology* 17; 318A, 2004.

264. Ross JS, Sheehan CE, Kaur P, Fisher HAG, Kaufman, Jr. RP, Kallakury BVS. Downregulation of CD138 and CD10 in prostatic adenocarcinomas (PACS): Utility of CD138 as a basal cell marker in prostate tissue. *Modern Pathology* 17; 174A, 2004.
265. Ross JS, Gray K, Beddah S, Schenkein D, Webb I, Gray G, Leschly N, Mosher R, Meyer R, Deeds J. Prostate specific membrane antigen (PSMA) expression in non-prostate cancers. Accepted for platform presentation. *Modern Pathology* 17; 326A, 2004.
266. Stec J, Ross JS, Pusztai L, Ayers M, Metivier J, Clark E, Linette E, Sneige N, Valero V, Hess K, Hortobagyi GN, Damokosh A, Symmans WF. Biopsy Method Collection Comparison of a Gene Expression Profile based Prediction of Complete Pathologic Response to Neoadjuvant Taxol/FAC Chemotherapy in Breast Cancer. *Modern Pathology* 17; 50A, 2004.
267. Symmans WF, Fitterman DJ, Pusztai L, Stec J, Clark E, Dunmire V, Sneige N, Albarracin C, Rajan R, Linette G, Ross JS, Zhang W, Hortobagyi GN, Ayers M. Expression of the PI subunit of γ -aminobutyric acid type A receptor (GABA π) is increased in breast cancers with combined estrogen receptor (ER) negative and HER-2/*neu* negative phenotype. *Modern Pathology* 17; 50A, 2004.
268. Symmans WF, Sneige N, Ayers M, Pusztai L, Clark E, Stec J, Linette G, Hortobagyi GN, Ross JS. Reliable measurement of estrogen receptor (ER) and Her-2/*neu* in needle biopsies using oligonucleotide and cDNA microarrays. *Modern Pathology* 17; 50A, 2004.

PEER REVIEWED JOURNAL PUBLICATIONS

1. Ross JS and Goldman JK: Compensatory Renal Hypertrophy in Hypophysectomized Rats. *Endocrinology* 87:620, 1970.
2. Ross JS and Goldman JK: Effect of Streptozotocin Induced Diabetes on Kidney Weight and Compensatory Hypertrophy. *Endocrinology* 88:1079, 1971.
3. Ross JS, Vancura P and Malt RA: Accelerated Transport of α -Aminoisobutyric Acid During Compensatory Renal Hypertrophy. *Proc Soc Exp Biol Med* 142:632, 1973.
4. Ross JS and Ellman L: Leukemic Infiltration of the Lungs in the Chemotherapeutic Era. *Am J Clin Path* 61:235, 1974.
5. Ross JS, Bucher NLR and Malt RA: Compensatory Renal Hypertrophy in Eviscerated Rats. *Can Res* 34:502-505, 1972.
6. Nash G and Ross JS: Herpetic Esophagitis: A Common Cause of Esophageal Ulceration. *Human Path* 5:339, 1974.
7. Ross JS, Malamud D, Caulfield JB and Malt RA: Differential Labeling with Orotic Acid and Uridine in Compensatory Renal Hypertrophy. *Am J Physiol* 229:952-954, 1975.
8. Ross JS and Prout GR: Retroperitoneal Fat Necrosis Producing Ureteral Obstruction. *J Urol* 115:524, 1976.
9. Buchholz TW, Malamud D, Ross JS and Malt RA: Onset of Cell Proliferation in the Shortened Gut: Growth After Subtotal Colectomy. *Surgery* 80:601-607, 1976.
10. Ross JS: Atrioventricular Node Mesothelioma with Congenital Complete Heart Block and Sudden Death. *Am J Dis Child* 131:1209, 1977.
11. Oscarson JEA, Veen HF, Williamson RCN, Ross JS and Malt RA: Compensatory Post Resectional Hyperplasia and Starvation Atrophy in Small Bowel: Dissection from Endogenous Gastrin Levels. *Gastroent* 72:890-895, 1977.
12. Ross JS: Massive Upper Gastrointestinal Hemorrhage From a Granular Cell Tumor of the Stomach. *Am J Gastroent* 68:595, 1977.
13. Robboy SJ, Ross JS, Prat J, Keh PC and Welch WR: Urogenital Sinus Origin of Mucinous and Ciliated Cysts of the Vulva. *OB and GYN* 51:347, 1978.
14. Williamson RCN, Bauer FL, Ross JS and Malt RA: Proximal Enterectomy Stimulates Distal Hyperplasia More Than Bypass or Pancreatobiliary Diversion. *Gastroenterol* 74:16-23, 1978.
15. Williamson RCN, Bauer FL, Ross JS and Malt RA: Contributions of Bile and Pancreatic Juice to Cell Proliferation in Ileal Mucosa. *Surgery* 83:570-576, 1978.
16. Williamson RCN, Bauer FL, Oscarson JEA, Ross JS and Malt RA: Promotion of Colonic Neoplasia by Resection of the Proximal Small Bowel. *Cancer Research* 38:3212-3217, 1978.

17. Breckenridge RL and Ross JS: Idiopathic Pulmonary Hemosiderosis in Siblings - First Report of Familial Occurrence. *Chest* 75:636, 1979.
18. Oscarson JEA, Veen HF, Ross JS and Malt RA: Ileal Resection Potentiates 1, 2-Dimethylhydrazine-induced Colonic Carcinogenesis. *Annals of Surgery* 189:503-508, 1979.
19. Williamson RCN, Bauer FL, Ross JS, Watkins JB and Malt RA: Enhanced Colonic Carcinogenesis with Azoxymethane in Rats after Pancreatic-Biliary Diversion to Mid Small Bowel. *Gastroenterol* 76:1386-1392, 1979.
20. Terpstra OT, Peterson-Dahl E, Ross JS, Williamson RCN and Malt RA: Distal Colonic Hyperplasia after Colostomy Closure: A Promoter of Chemical Carcinogenesis. *Surgical Forum* 30:130-131, 1979.
21. Spector JE, Zimble H and Ross JS: Cytoxan Induced Pulmonary Toxicity. *JAMA* 244:1121, 1980.
22. Williamson RCN, Bauer FL, Terpstra OT, Ross JS and Malt RA: Contrasting Effects of Subtotal Enteric Bypass, Enterectomy, and Colectomy on Azoxymethane Induced Carcinogenesis. *Cancer Research* 40:538-543, 1980.
23. Schattenkerk, M.E., Li, A.K.C., Jeppsson, B.W., Koroly, M.J., Ross, J.S., and Malt, R.A.: Saliva Aggravates Chemical Carcinogenesis of the Colon. *Surgical Forum*. 31, 1980.
24. Schattenkerk ME, Li AKC, Jeppsson BW, Eggink WF, Jameson CG, Ross JS and Malt RA: Cholecystectomy Has No Influence on Frequency of Chemically Induced Colon Cancer in Mice. *Brit J Cancer* 42:791-793, 1980.
25. Spector JI, Zimble H, Levine R, Ross JS, Valigorsky JM and Cole LM: Sweet's Syndrome. Association with Acute Leukemia. *JAMA* 244:1131, 1980.
26. Ross JS, Fanning WL, Beautyman W and Craighead J: Fatal Massive Hepatic Necrosis form Varicella-Zoster Hepatitis. *Am J Gastroenterol* 74:423, 1980.
27. Ross JS and Leitner D: Carcinoid With Carcinoma: A Case of Tumor to Tumor Metastasis. *Arch Pathol Lab Med* 105:558, 1981.
28. Halpern JJ, Richardson EP Jr, Ellis J, Ross JS and Wray SH: Paraneoplastic Encephalomyelitis and Neuropathy. *Arch Neurol* 38:773, 1981.
29. Terpstra OT, Peterson Dahl E, Williamson RCN, Ross JS and Malt RA: Colostomy Closure Promotes Cell Proliferation and Dimethylhydrazine-induced Carcinogenesis in Rat Distal Colon. *Gastroenterol* 81:475-480, 1981.
30. Oscarson JEA, Veen HF, Ross JS and Malt RA: Dimethylhydrazine-induced Colonic Carcinoma in the Rat: Dissection from Endogenous Gastrin Levels. *Surgery* 91:525-530, 1982.
31. Terpstra OT, Peterson Dahl E, Williamson RCN, Ross JS and Malt RA: Anastomotic Suture Line Tumors in Experimental Colon Carcinogenesis. *Proc Eur Soc Surg Onc*, 1982.

32. Li AKC, Schattenkerk ME, Huffman RG, Ross JS and Malt RA: Hypersecretion of Submandibular Saliva in Male Mice Trophic Response in Small Intestine. *Gastroenterol* 84:949-955, 1983.
33. King WWK, Boelhouwer RW, Kingsnorth AN, Ross JS, Young VR and Malt RA: Nutritional Efficacy and Hepatic Changes During Intra gastric, Intravenous, and Prehepatic Feeding in Rats. *J Paranteral Enteral Nutrition* 7:443-446, 1983
34. Kingsnorth AN, McCann PP, Diekema KA, Ross JS and Malt RA: Effects of a-Difluoromethylornithine on the Growth of Experimental Wilm's Tumor and Renal Adenocarcinoma. *Cancer Res* 43:4031-4034, 1983.
35. Kingsnorth AN, King WWK, Diekema KA, McCann PP, Ross JS and Malt RA: Inhibition of Ornithine Decarboxylase with 2Difluoromethyl- ornithine: Reduced Incidence of Dimethylhydrazine-induced Colon Tumors in Mice. *Cancer Res* 43:2545-2549, 1983.
36. Ross JS, Spector JL, Zimble H and Valigorsky J: Hepatic Iron Overload in Sideroblastic Anemia, A Distinct Clinicopathologic Condition. *Hepatology* 215, 1983.
37. Warner KW, Hiadak GL and Ross JS: Massive Glomus Tumor of the Stomach: 20 Year Follow up and Autopsy Findings. *Am J Gastroenterol* 79:253, 1984.
38. Ford WDA, Boelhouwer RV, King WWK, deVries JE, Ross JS and Malt RA: Total Parenteral Nutrition Inhibits Intestinal Adaptive Hyperplasia in Young Rats: Reversal by Feeding. *Surgery* 96:527-34, 1984.
39. deVries JE, Ford A, Boelhouwer RV, King WWK, Oscarson JEA, Ross JS, Thorell J and Malt RA: Inverse Relation of Jejunal DNA Content and Maturation to Serum Gastrin Levels in Suckling and Weanling Rats. *Digestive Dis and Sci* 30:1079-1084, 1985.
40. Leibowitz EW and Ross JS: Anterior Sacral Meningocele Contiguous with a Pelvic Hamartoma. *J Neurosurg* 61:188, 1984.
41. Warner KW, Noyes DT and Ross JS: Cysts of Tunica Albuginea Testes: Three Cases with a Review of the Literature. *J Urology* 132:131, 1984.
42. Leitner DW, Ross JS and Neary JR: Granulomatous Radial Arteritis with Bilateral Non-traumatic True Arterial Aneurysms Within the Anatomical Snuff-box. *J Hand Surg*, 1985.
43. Ross JS and Kurian S: Clear Cell Hepatocellular Carcinoma: Sudden Death from Hypoglycemia. *Am J Gastroenterol* 80:188, 1985.
44. Kingsnorth AN, Abu-Kalaf M, Ross JS and Malt RA: Potentiation of 1,2 - Dimethylhydrazine-Induced Anal Carcinoma by Epidermal Growth Factor in Mice. *Surgery* 97:696-700, 1985.
45. Shickmanter B, Wachtel S, Cahill L, Ross JS, Shreefter M, Booth E and Scully RE: H-Y Antigen in a 46 XX Female with Dysgenetic Ovaries. *J Clin Endo Metab* 60:1042, 1985.

46. King WWK, deVries JE, Boelhouwer RV, Ford WDA, Kingsnorth AN, Ross JS and Malt RA: Effects of Submandibular Sialadectomy on N-methyl-N'-Nitro-N- Nitrosoguanidine Induced Duodenal Carcinogenesis in Mice. *Brit J Cancer* 51:429-432, 1985.
47. Ford WDA, deVries JE, Ross JS and Malt RA: Intestinal Resection in the Neonatal Rat: Stimulus for Precocious Intestinal Maturation. *J Ped Gastroentrol and Nutrit* 4:628-633, 1985.
48. deVries JE, Schattenkerk ME, Li AKC, Ford A, Ross JS, Jeppson BW, Jamieson CG, Koroly MJ and Malt RA: Lack of Submandibular Saliva Diminishes 1,2-Dimethylhydrazine Induced Colonic Carcinogenesis in Male Mice. *Brit J Cancer* 1985.
49. Chester JC, Ross JS, Malt RA and Weitzman SA: Acute Colitis Produced by Chemotactic Peptides in Rats and Mice. *Am J Path* 121:284-290, 1985.
50. Ford WDA, deVries JE, Ross JS and Malt RA: Effect of Luminal Contents on Postresectional Longitudinal and Mucosal Growth in Ileum of Suckling Rats. *Surgery* 98:935-941, 1985.
51. Chester JC, Gaissert JA, Ross JS and Malt RA: Promotion of Experimental Pancreatic and Bronchial Cancer by Epidermal Growth Factor. *Surgical Forum*. 36:421-422, 1985.
52. Kingsnorth AN, Abu-Khalaf M, LaMuraglia GM, McCann PP, Diekma KA, Ross JS and Malt RA: Inhibition of Ileal and Colonic Ornithine Decarboxylase Activity by α -Difluoromethylornithine in Rats: Transient Atrophic Changes and Loss of Postresectional Adaptive Growth. *Surgery* 99:721-727, 1986.
53. Chester JF, Gaissert JA, Ross JS, Malt RA and Weitzman SA: Augmentation of 1,2-Dimethylhydrazine Induced Colon Cancer by Experimental Colitis in Mice: Role of Dietary Vitamin E. *JNCI* 76:939-942, 1986.
54. Norris CM, Mustoe TA, Ross JS and Goodman ML: Desmoplastic Squamous Cell Carcinoma of the Tongue Stimulating Mytosis or Fasciitis. *Head & Neck Surg* 9:51, 1986.
55. Malt RA, Kingsnorth AN, LaMuraglia GM, Lacaine F and Ross JS: Chemoprevention and Chemotherapy by Inhibition of Ornithine Decarboxylase Activity and Polyamine Synthesis: Colonic, Pancreatic, Mammary, and Renal Carcinomas. *Adv Enzyme Reg* 24:93-102, 1986.
56. Chester JF, Gaissert HA, Ross JS and Malt RA: Pancreatic Cancer in the Syrian Hamster Induced by N-Nitrosobis (2--oxypropylamine): Cocarcinogenic Effect of Epidermal Growth Factor. *Can Res* 46:2954-2957, 1986.
57. Kingsnorth AN, LaMuraglia GM, Ross JS and Malt RA: Vanadate Supplements and 1,2-Dimethylhydrazine-induced Colon Cancer in Mice: Increased Thymidine Incorporation Without Enhanced Carcinogenesis. *Br J Cancer* 53:683-686, 1986.
58. Ross JS, Szyfelbein WM, Booth E and Taft P.D.: Cytologic Diagnosis of Malignant Glioma in Cerebrospinal Fluid. *Cytopathology*, C86-7, *Am Soc Clin Path*, 1986.

59. Chester JF, Gaissert HA, Ross JS, Malt RA and Weitzman SA: N-(4-(S-nitro-2-furyl)-2-thiazolyl) Formide-induced Bladder Cancer in Mice: Augmentation by Sutures Through the Bladder Wall. *J Urol* 137:769-771, 1987.
60. Spector JI, Zimble H, DeLeo M and Ross JS: Skin Metastases From Transitional Cell Bladder Cancer. *Urology* 29:215, 1987.
61. Ross JS, King TM, Spector JI, Zimble H and Basile RM: Plasmacytoma of the Breast: An Unusual Case of Recurrent Myeloma. *Arch Int Med* 147:1838, 1987.
62. Malt RA, Chester JF, Gaissert HA and Ross JS: Augmentation of Chemically induced Pancreatic and Bronchial Cancers by Epidermal Growth Factor. *Gut* 28:249-251, 1987.
63. Szyfelbein WM and Ross JS: Carcinoids, Atypical Carcinoids, and Small Cell Carcinomas of the Lung: Differential Diagnosis of Fine Needle Aspiration Biopsies. *Diag Cytopath* 4:1, 1988.
64. Basile RM and Ross JS: Fibrolamellar Oncocytic Hepatocellular Carcinoma: A Surgical Disease. *Contemp Surg* 32:26, 1988.
65. Szyfelbein WM and Ross JS: Lyme Disease Meningoencephalitis Stimulating Malignant Lymphoma. *Modern Pathol* 1:464, 1988.
66. Ross JS and Szyfelbein WM: Intra nuclear Inclusions in Carcinoid Tumors. *Diag. Cytopath*, 1989.
67. Chester JF, Gaissert HA, Ross JS and Malt RA: Colonic Cancer Induced by 1,2-Dimethylhydrazine: Promotion by Experimental Colitis. *Brit J Cancer* 59:704-705, 1989.
68. Ross JS, Sadighi P, August D and Pellish LJ: Barrett's Esophagus with Small Cell Undifferentiated Carcinoma. *Bull Berk Med Ctr* 1989.
69. Ross JS and Nieburgs HE: Prognosis in Breast Cancer Predicted by Morphologic Assessment of the Cell Cycle. *Cancer Detection and Prevention* 14:186, 1989.
70. Spector JI, Valigorsky JM, Ross JS, Bellizzi JA: The need to biopsy. *Am J Hematol* 32:316, 1989.
71. Bui HX, Ross JS, delRosario A, Sonbati H, Lee CY, George M: Helicobacter pylori affects the quality of experimental gastric ulcer healing: a quantitative histologic analysis in a new animal model. *J Exp Molec Path* 55:261-268, 1991
72. Remick SC, Harper G, Abdulla M, McSharry J, Ross JS, Ruckdeschel JC: Metastatic breast cancer in a young HIV-seropositive patient. *JNCI*, 83(6):147-148, 1991.
73. Horner SA, Fisher HAG, Barada JH, Eastman AY, Miglioizzi J, Ross JS: Verrucous carcinoma of the bladder. *J Urology*, 145:1261-1263, 1991.

74. Ross JS, Magro CS, Sorensen SS and Szyfelbein WS: Cerebrospinal Fluid Pleocytosis in Aseptic Meningitis: Cytomorphic and Immunocytochemical Features. *Diagn Cytopath*, 7(5):532-535, 1991.
75. Kim DN, Schmee J, Lee CS, Solis O, Ross JS, Thomas WA: Reductions in Serum Thromboxane, Prostacyclin and Leukotriene B₄ Levels in Swine Fed a Fish Oil Supplement to an Atherogenic Diet. *Exp and Molec Path* 55:1-12, 1991.
76. Nazeer T, Barada JH, Fisher HAG, Ross JS: Prostatic Carcinosarcoma: Case Report and Review of the Literature. *J Urol* 146:1370-1373, 1991.
77. Kim DN, Schmee J, Lee CS, Eastman AE, Ross JS, Thomas WA. Comparison of Fish Oil and Supplements on Hyperlipidemic Diet Induced Atherosclerosis in Swine. *Athero* 89:191-201; 1991.
78. Solis OG, Bui HX, Malfetano JH and Ross JS. Case Report: Extragenital Primary Mixed Malignant Mesodermal Tumor. *Gynecologic Oncology* 43:182-185, 1991.
79. Figge J, Bakst G, Weisheit D, Solis OG, Ross JS. Image Analysis Quantitation of Immunoreactive Retinoblastoma Protein in Human Thyroid Neoplasms with a Streptavidin-Biotin-Peroxidase Staining Technique. *Amer J Path* 139(6):1213-1219, 1991.
80. Ross JS, Bui HX, del Rosario A, Sonbati H, George M, Lee CY: *Helicobacter pylori* - its role in the pathogenesis of peptic ulcer disease in a new animal model. *Am J Pathol* 141(3):721-727, 1992.
81. Veloso JD, Solis O, Barada JH, Fisher HAG, Ross JS: DNA ploidy of renal oncocytomas and renal cell carcinomas by image analysis. *Arch Path Lab Med* 116:154-158, 1992.
82. Ross JS, Nazeer T, Rosano TG, Malfetano J: Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial carcinoma. *Am J Clin Path* 97(6):764-769, 1992.
83. Ross JS, delRosario A, Bui HX, Sonbati H, Solis O: Primary Hepatic Leiomyosarcoma in a Child with AIDS. *Human Pathology* 23:69-72, 1992.
84. Kallakury BVS, Bui HX, del Rosario A, Ross JS. Primary Gastric Adenosarcoma: First Case Report. *Arch Path & Lab Med* 117(3): 299-301, 1993.
85. Bui HX, Lee CY, del Rosario A, Abdulla M, Ballouk F, Sheehan C, Ross JS. Histologic and Ultrastructural Features of Experimental Duodenal Ulcers in Sprague Dawley Rats. *Experimental and Molecular Pathology* 59(2):136-145, 1993.
86. del Rosario A, Bui HX, Abdulla M, Khan M, Ross JS. Sulfur-Rich Prostatic Intraluminal Crystalloids: A Surgical Pathologic and Electron Probe X-Ray Microanalytic Study. *Hum Path* 24(11), 1159-1167, 1993 (Also featured as cover article).
87. Ballouk F, Ambros RA, Malfetano JH, Ross JS. Evaluation of Prognostic Indicators in Squamous Carcinoma of the Vulva Including Nuclear DNA Content. *Mod Pathol* 6(3):371-375, 1993.

88. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HAG. Contribution of Her-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. *Cancer* 72(10):3021-3027, 1993.
89. Venezia RA, Ross JS. Serologic diagnosis of *Helicobacter pylori*-associated gastrointestinal disease. *Clinical Immunology Newsletter* 13(9/10); 125-129; 1993.
90. Schmee J, Kim DN, Ross JS, Thomas WA. Exponential relationship between plasma cholesterol levels and atherosclerotic lesion size in hyperlipidemic swine. *Experimental and Molecular Pathology* 59: 177-185, 1993.
91. Kim DN, Schmee J, Baker JE, Lunden GM, Sheehan CE, Lee CS, Eastman A, Solis O, Ross JS, Thomas WA. Dietary Fish Oil Reduces Microthrombi Over Atherosclerotic Lesions in Hyperlipidemic Swine Even in the Absence of Plasma Cholesterol Reduction. *Exp Molec Pathol* 59:122-135; 1993
92. Weinberg E, Hoisington S, Eastman AY, Rice DK, Malfetano J, Ross JS. Uterine Cervical Lymphoepithelial-Like Carcinoma: Absence of Epstein Barr Genomes. *Amer J Clin Pathol* 99(2):195-199, 1993.
93. Bui HX, Ballouk F, Abdulla M, del Rosario A, Khan M, Jennings TA, Ross JS. Nuclear DNA Content and Clinical Follow Up in Resected Pancreatic Adenocarcinoma. *Anal Quant Cytol Histol* 15(6):389-395, 1993.
94. Khan M, Bui HX, Abdulla M, del Rosario A, Ballouk F, Sim YJ, Ross JS. Role of DNA Content Determination by Image Analysis in Confirmation of Dysplasia in Barrett's Esophagus. *Modern Pathology* 7(2):169-174; 1994.
95. Nazeer T, Church K, Amato C, Ambros RA, Rosano TG, Malfetano JH, Ross JS. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: Predictors of tumor aggressiveness. *Mod Pathol* 7(4); 469-474, 1994.
96. Kallakury BVS, Figge J, Ross JS, Fisher HAG, Figge HL, Jennings, TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. *Human Pathology* 25(1):92-97; 1994.
97. Ambros RA, Vigna PA, Figge J, Kallakury BVS, Mastrangelo A, Eastman AY, Malfetano J, Figge HL, Ross JS. Observations of tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. *Cancer* 73(6):1686-1692; 1994.
98. Kallakury BVS, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA, Figge J. Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high grade prostatic adenocarcinoma. *Diagn Mol Pathol (Amer J Surg Pathol Part B)*. 3(4):227-232;1994.
99. Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, Fisher HAG. Prediction of pathologic stage and post-prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. *Cancer* 74(10):2811-2818; 1994

100. Ambros RA, Ballouk F, Malfetano JH, Ross JS. Significance of papillary (Villoglandular) differentiation in endometrial carcinoma of the uterus. *Am J Surg Path* 181(6):569-575; 1994.
101. Abdulla M, Bui HX, del Rosario AD, Wolf BC, Ross JS. Renal Angiomyolipoma: DNA content and immunohistochemical study of classic and multicentric variants. *Arch Pathol Lab Med* 118:735-739; 1994.
102. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HAG, Nazeer T, Jennings TA, Ingle R, Kim DN. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage and clinical outcome. *Mod Pathol* 7(8):835-841, 1994.
103. Ballouk F, Ross JS, Wolf BC. Ovarian endometriotic cysts: An analysis of cytologic atypia and DNA ploidy patterns. *Am J Clin Path* 102(4):415-419; 1994.
104. del Rosario AD, Bui HX, Singh J, Ginsburg R, Ross JS. Intracytoplasmic eosinophilic "Hyaline" globules in cartilaginous neoplasms: A surgical pathologic, ultrastructural and electron probe x-ray microanalytic study. *Human Pathology* 25:1283-1289, 1994.
105. Vigna PA, Kusior MF, Collins MB, Ross JS. Peripheral Nerve Hemangioma: Potential for Clinical Aggressiveness. *Arch Pathol Lab Med.* 118:1038-1041; 1994.
106. Smith DM and Murphy WM. (participating pathologists: Banks ER, Bigler S, Civantos F, Gal A, Hackett RL, Ho CK, Johnson E, Marcial MA, Muller R, Murphy WM, Oyasu R, Ross JS, Schned A, Schultz DS, Shabaik AS, Speights VO, Tomaszewski JE, Unger P). Histologic changes in prostate carcinomas treated with Leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation. *Cancer* 73(5):1472-1477; 1994.
107. Figge J, del Rosario AD, Gerasimov G, Dedov I, Bronstein M, Troshina K, Alexandrova G, Kallakury BVS, Bui HX, Bratslavsky G, Ross JS. Preferential expression of cell adhesion molecule CD44 in papillary thyroid carcinoma. *Experimental and Molecular Pathology* 61: 203-211, 1994.
108. Kim DN, Eastman AE, Baker JE, Mastrangelo A, Sethi S, Ross JS, Schmee J, Thomas WA. Fish oil, atherogenesis and thrombogenesis. *Annals of NY Academy of Science*, 748:474-481; 1995.
109. Slominski A, Ross JS, Mihm MC Jr. Cutaneous melanoma: pathology, relevant prognostic indicators and progression. *Brit Med Bulletin* 51(3); 548-569; 1995.
110. del Rosario A, Bui HX, Petrocine S, Sheehan C, Pastore J, Singh J, Ross JS. True synovial metaplasia of breast implant capsules: A light and electron microscopic study. *Ultrastructural Pathology* 19:83-93, 1995.
111. Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HAG, Bui HX. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. *Human Pathology* 26(9):940-944; 1995.
112. Ross JS, Eastman A, Mastrangelo A, Baker JE, Kim DN. Effects of nonsteroidal antiinflammatory drugs on monocyte-endothelial cell interaction. *Atherosclerosis III: Recent*

Advances in Atherosclerosis Research. vol 748 Annals of the New York Academy of Sciences, 559-561, 1995.

113. Ross JS, Nazeer T, Figge HL, Fisher HAG, Rifkin MD. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies: correlation with tumor grade, stage, PSA level and DNA ploidy status. *Am J Clin Pathol* 104:36-41, 1995.

114. Ballouk F, Boguniewicz A, Ross JS, Jennings TA. Image analysis quantification in hormone receptor assay of mucinous carcinoma of the breast: Comparison with biochemical analysis. *Analytical and Quantitative Cytology and Histology*. 17(3):151-156;1995.

115. Ambros RA, Ross JS, Kallakury BVS, Malfetano J, Kim Y, Hwang J, Breese K, Figge J. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. *Modern Pathology* 8(4): 441-445, 1995.

116. Ross JS. Basic science review for clinical pathologists. *Am J Clin Pathol* 103:379, 1995.

117. Gerasimov G, Bronstein M, Troshina K, Alexandrova G, Dedov I, Jennings TA, Kallakury BVS, Izquierdo R, Boguniewicz A, Figge H, Robinson L, Breese K, Ross JS, Figge J. Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two indicators of poor prognosis. *Experimental and Molecular Pathology* 62: 52-62, 1995.

118. Ermack G, Gerasimov G, Troshina K, Jennings T, Robinson L, Ross JS, Figge J. Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and non-neoplastic lesions of the human thyroid. *Cancer Research* 55:4594-4598, 1995.

119. Ermack G, Jennings T, Robinson L, Ross JS, Figge J. Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. *Cancer Research* 56:1037-1042, 1996.

120. Kallakury BVS, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, Figge HL, Nazeer T, Ross JS. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with P53 protein accumulation. *Modern Pathol* 9(1):41-47, 1996.

121. Chhieng DC, Ross JS, Ambros RA. bcl-2 expression and the development of endometrial carcinoma. *Modern Pathol* 9(4):402-406, 1996.

122. Ross JS, del Rosario AD, Sanderson B, Bui HX. Selective expression of CD44 cell adhesion molecule in thyroid papillary carcinoma fine needle aspirates. *Diagnostic Cytopathology* 14(4): 287-291, 1996

123. Ross JS, Cheung C, Sheehan C, del Rosario AD, Bui HX, Fisher HAG. E-cadherin cell adhesion molecule expression as a diagnostic adjunct in urothelial cytology. *Diagnostic Cytopathology*, 14(4): 310-315, 1996.

124. Ross JS, del Rosario AD, Bui HX, Kallakury BVS, Okby NT, Figge J. CD44 cell adhesion molecule expression in urinary bladder transitional cell carcinoma. *Modern Pathology* 9(8): 854-860, 1996.

125. Ross JS. DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis assessment. *Oncology* 10(6), 867-887, 1996.
126. Ross JS. Evolving delivery systems for clinical laboratories: The Albany Medical Center laboratory network. *The Journal of Clinical Laboratory Management Association*, 10(5):525-533, 1996.
127. Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG, Kaufman R, Figge H, Ross JS. Decreased levels of CD44 protein and mRNA in prostate carcinoma: Correlation with tumor grade and ploidy. *Cancer* 78(7): 1461-1469, 1996.
128. Bajas MA, Rifkin MD, Vo T, Cheng S, Czerwiskyj C, Ross JS. Should prostate specific antigen or prostate specific antigen density be used to determine which prostate should undergo biopsy during prostate ultrasound. *Radiology* 10:254, 1996.
129. Ambros RA, Sheehan CE, Kallakury BVS, Ross JS, Malfetano JH, Paunovich E, Figge J. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. *Modern Pathol* 9(12):1165-1169; 1996.
130. Hou J, Kallakury BVS, Bui HX, del Rosario AD, Fisher HAG, Ross JS. E-cadherin and p53 expression in pure testicular seminoma. *Journal of Urologic Pathology*, 5:109-118, 1996.
131. Kremer JM, Malamood H, Maliakkal B, Rodgers JB, Ross JS, Cooper JA. Fish oil dietary supplementation for prevention of indomethacin induced gastric and small bowel toxicity in healthy volunteers. *J Rheumatology* 23(10):1770-1773, 1996.
132. Anderson DR, Schwartz J, Cottrill CM, McClain SA, Ross JS, Magidson JG, Klainer A, Bisaccia E. Silicone granuloma in acral skin in a patient with silicone-gel breast implants and systemic sclerosis. *Int J Dermatology* 35(1):36-8, 1996.
133. Ross JS, Sheehan C, Hayner-Buchan A, Ambros RA, Kallakury BVS, Kaufman R, Fisher HAG, Muraca PJ. HER-2/*neu* gene amplification status in prostate cancer by fluorescence in-situ hybridization. *Human Pathol* 28(7):827-833; 1997.
134. Tran TA, Kallakury BVS, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas (NSCLCs). *Human Pathology* 28(7):809-814; 1997.
135. Cohen MB, Griebing TL, Ahaghotu CA, Rokhlin OW, Ross JS. Cellular adhesion molecules in urologic malignancies. (Review Article) *A J Clin Path* 107(1); 56-63, 1997.
136. Ross JS, Sheehan CE, Hayner-Buchanan AM, Ambros RA, Kallakury BVS, Kaufman, Jr. RP, Fisher HAG, Rifkin MD, Muraca PJ. Prognostic significance of HER-2/*neu* gene amplification status by fluorescence in-situ hybridization in prostatic cancer. *Cancer*, 79(11): 2162-2170, 1997.
137. White MD, Loughlin MW, Kallakury BVS, Ross JS, Mandell J. Case Report: Bilateral large-cell calcifying sertoli cell tumor of the testis in a seven year old male. *The Journal of Urology* 158(4):1547-1548, 1997.

138. Chhieng DC, Ross JS, McKenna BJ. CD44 immunostaining of thyroid fine needle aspirates differentiates thyroid papillary carcinoma from other lesions with nuclear grooves and inclusions. *Cancer Cytopathology* 81(3):157-162, 1997.
139. Katsen-Jolly J, Aubrey MT, Conti DJ, Rosano TG, Ross JS, Freed BM. Reversal of hyperglycemia in diabetic NOD mice by human proinsulin gene therapy. *Transplantation Proceedings*, 29:2216-2218, 1997.
140. Riben MW, Malfetano JA, Nazeer T, Ambros RA, Ross JS. Identification of HER-2/*neu* oncogene amplification by fluorescence in-situ hybridization in stage I endometrial carcinoma. *Modern Pathology* 10(8):823-831, 1997.
141. Kallakury BVS, Sheehan CE, Ambros RA, Fisher HAG, Kaufman, Jr. RP, Ross JS. Prognostic significance of p34^{cdc2} and cyclin D1 protein expression in prostatic adenocarcinomas. *Cancer* 80(4): 753-763, 1997.
142. Brien TP, Kallakury BVS, Lowry CV, Ambros RA, Muraca PJ, Malfetano JH, Ross JS. Telomerase activity in benign endometrium and endometrial carcinoma. *Cancer Research* 57: 2760-2764; 1997.
143. Kallakury BVS, Brien TP, Lowry CV, Muraca PJ, Fisher HAG, Kaufman, Jr. RP, Ross JS. Telomerase activity in human benign prostatic tissue and prostatic adenocarcinomas (PACs). *Diagnostic Molecular Pathology* 6(4): 192-198, 1997.
144. Ross JS. The ASCP Resident Physician Section: Results of surveys pertaining to graduated responsibility for residents in anatomic pathology. (editorial) *Am J Clin Pathol* 107(6):630-631, 1997.
145. Tran TA, Kallakury BVS, Carter J, Wolf BC, Ross JS. Coexistence of granular cell tumor and ipsilateral infiltrating ductal carcinoma of the breast. Case report. *Southern Medical Journal* 90(11):1149-1151; 1997.
146. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. Her-2/*neu* (c-*erb* B-2) gene amplification characterized by fluorescence *in situ* hybridization: poor prognosis in node-negative breast carcinomas. *J Clin Oncol* 15(8): 2894-2904; 1997.
147. Scalzo DA, Kallakury BVS, Gaddipati RV, Sheehan CE, Keys HM, Savage D, Ross JS. Cell proliferation rate by MIB-1 immunohistochemistry predicts post radiation recurrence of prostatic adenocarcinomas. *American Journal of Clinical Pathology* 109(2):163-168, 1998.
148. Ross JS. New roles for pathologists in the 21st century. (editorial). *Human Pathology*, 29(2):107-109, 1998.
149. Kallakury BVS, Sheehan CE, Ambros RA, Fisher HAG, Kaufman, Jr. RP, Muraca PJ, Ross JS. Correlation of p34^{cdc2} cyclin dependent kinase overexpression, CD44s downregulation and HER-2/*neu* oncogene amplification with recurrence in prostatic adenocarcinomas. *Journal of Clinical Oncology* 16(4):1302-1309, 1998.

150. Ingle R, Jennings TA, Goodman ML, Pilch BZ, Bergman S, Ross JS. CD44 expression in sinonasal inverted papillomas and associated squamous cell carcinoma. *Am J Clin Pathol* 109 (3), 309-314, 1998.
151. Tran TA, Jennings TA, Ross JS, Nazeer T. Pseudomyxoma ovarii-like posttherapeutic alteration in prostatic adenocarcinoma. A distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. *Am J Surg Pathol* 22(3): 347-354, 1998.
152. Brien TP, Reddy PP, Vincent PA, Lewis EP, Ross JS, Saba TM. Lung matrix deposition of normal and alkylated plasma fibronectin: response to postsurgical sepsis. *Am J Physiol* 274:L432-L443, 1998.
153. Brien TP, Depowski P, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. *Mod Pathol*, 11(9):870-877, 1998.
154. Tran TA, Kallakury BVS, Ambros RA, Ross JS. Prognostic significance of tumor necrosis factors and their receptors in non small cell lung carcinomas. *Cancer* 83(2):276-282, 1998.
155. Meyer DR, Bui HX, Carlson JA, Ratcliff CD, Guevarra MC, del Rosario AD, Ross JS, Mihm, Jr, MC. Silicon granulomas and dermatomyositis-like changes associated with chronic eyelid edema after silicone breast implant. *Ophthalmic Plastic and Reconstructive Surgery* 14(3):182-188; 1998.
156. Ross JS, Fletcher JA. The Her-2/*neu* oncogene: Prognostic factor, predictive factor and target for therapy. *The Oncologist*, 3:237-252, 1998.
157. Ross JS. Molecular pathology and managed care: Challenges and opportunities. *Diagnostic Molecular Pathology* 7(4):189-191, 1998.
158. Carlson JA, Ambros R, Malfetano J, Ross J, Grabowski R, Lamb P, Figge H, Mihm, JR., MC. Vulvar lichen sclerosus and squamous cell carcinoma: A cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. *Hum Pathol* 29(9):932-948, 1998.
159. Tran TA, Ross JS, Carlson JA, Mihm, Jr, MC. Mitotic cyclins and cyclin- dependent kinases in melanocytic lesions. *Human Pathology* 29(10):1085-1090, 1998
160. Rifkin MD, Tessler FN, Tublin ME, Ross JS. US Case of the Day. *Radiographics* 18:1605-1607, 1998.
161. Ross JS, Fletcher JA. The Her-2/*neu* oncogene: Prognostic factor, predictive factor and target for therapy. (invited submission) *Stem Cells* 16(6):413-428, 1998.
162. Slominski A, Wortsman J, Nickoloff B, McClatchey K, Mihm MC, Ross JS. Molecular pathology of malignant melanoma. *Am J Clin Path* 110(6):788-794; 1998.
163. Kallakury BVS, Ambros RA, Hayner-Buchan A, Sheehan CE, Malfetano JH, Ross JS. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrial subtypes. *Int J Gynecol Path* 17:320-326, 1998.

164. Epstein JA, Amin MB, Reuter VR, Mostofi FK, Bladder Consensus Committee (Algaba F, Allsbrook WC, Ayala AG, Becich MJ, Beltran AL, Boccon-Gibod L, Bostwick DG, Busch C, Davis CJ, Eble JN, Foster CS, Furusato M, Grignon DJ, Humphrey PA, Ishak HS, Johanasson SL, Jones EC, Koss LG, Levin HS, Murphy WM, Peterson RO, Renshaw A, Ro JY, Ross JS, Sesterhenn IA, Srigley JR, Suzigan S, Tomaszewski JB, Troncoso P, True LD, Weiss MA, Wheeler TM, Young RH). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 22(12):1435-1448, 1998.
165. Ross JS, Fletcher JA. The Her-2/*neu* oncogene: Prognostic factor, predictive factor and target for therapy. *Sem Cancer Biol*, 9:125-138; 1999.
166. Ross JS, Yang F, Kallakury BVS, Sheehan CE, Ambros RA, Muraca PJ. HER-2/*neu* oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. *Am J Clin Pathol* 111:311-316; 1999.
167. Kallakury BVS, Sheehan CE, Rhee SJ, Fisher HAG, Kaufman Jr. RP, Rifkin MD, Ross JS. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma. *Cancer* 85(7):1569-1576, 1999.
168. Ross JS, Sheehan CE, Ambros RA, Nazeer T, Jennings TA, Kaufman Jr., RP, Fisher HAG, Rifkin MD, Kallakury BVS. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. *Am J Surg Pathol* 23(3):296-301, 1999.
169. Harbeck N, Ross JS, Yurdseven S, Dettmar P, Polcher M, Kuhn W, Ulm K, Graeff H, Schmitt M. HER-2/*neu* gene amplification by fluorescence *in situ* hybridization allows risk-group assessment in node-negative breast cancer. *Int J Oncol* 14:663-671, 1999.
170. Mu XC, Brien TP, Ross JS, Lowry CV, McKenna BJ. Telomerase activity in benign and malignant cytologic fluids. *Cancer (Cancer Cytopathology)* 87(2):93-99, 1999.
171. Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors: Diagnostic utility and clinical applications. *Am J Clin Pathol* 112(Suppl 1): S68-S75, 1999.
172. Ross JS, Fletcher JA. HER-2/*neu* (c-erb-B2) gene and protein in breast cancer. *Am J Clin Pathol* 112 (Suppl 1):S53-S67, 1999.
173. Ross JS. Economic, regulatory, and practice issues in molecular pathology and diagnostics. *Am J Clin Pathol* (Suppl 1):S7-S10, 1999.
174. Tran Tien-Anh, Ayala AG, Amin MB, Nazeer T, Ro JY, Ross JS, Jennings TA. Utility of high-molecular weight 34βE12 in atypical small acinar proliferations in prostatic needle biopsies. *Applied Immunohistochemistry & Molecular Morphology* 7(3): 186-192, 1999.
175. Ross, JS. The impact of molecular diagnostic tests on patient outcomes. *Clinics in Laboratory Medicine* 19(4): 815-831, 1999.
176. Depowski PL, Brien TP, Sheehan CE, Stylos S, Johnson RL, Ross JS. Prognostic significance of p34^{cdc2} cyclin-dependent kinase and MIB1 overexpression, and HER-2/*neu* gene

amplification detected by fluorescence in-situ hybridization in breast cancer. *Am J Clin Pathol* 112:459-469, 1999.

177. Fiche M, Avet-Loiseau H, Heymann MF, Moussaly F, Digabel C, Joubert M, Class JM, Dravet F, Fumoleau P, Ross J, Maugard CM. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. *Int J Cancer* Oct 22; 84(5):511-5, 1999.

178. Tran T-A, Ross JS, Bohm JR, Carlson JA. Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma. *J Cutan Pathol* 26:391-397, 1999.

179. Ross JS. Financial determinants of outcomes in molecular testing. *Arch Pathol Lab Med* 123:1071-1075, 1999.

180. Depowski PL, Setzen G, Chui A, Koltai PJ, Dollar J, Ross JS. Familial occurrence of acinic cell carcinoma of the parotid gland. *Arch Pathol Lab Med* 123:1118-1120, 1999.

181. Brinker DA, Ross JS, Tran TA, Jones DM, Epstein JI. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy and grade? *J Urol* 162(6):2036-9, 1999.

182. Brien TP, Odze RD, Sheehan CE, Mc Kenna BJ, Ross JS. HER-2/*neu* gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. *Hum Pathol* 31(1):35-39, 2000.

183. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. *Cancer Cytopathology* 90(2):75-86, 2000.

184. Tran T-A, Ross JS, Sheehan CE, Carlson JA. Comparison of oncostatin M expression in keratoacanthoma and squamous cell carcinoma. *Mod Pathol* 13(4):427-432; 2000.

185. Ross JS. The HER-2/*neu* gene protein in breast cancer: Methods of detection and clinical significance. *J Clin Ligand Assay*, 2000.

186. Mu XC, Tran TA, Ross JS, Carlson JA. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. *J Cutan Pathol* 27:242-248, 2000.

187. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase II α expression in breast cancer: Correlation with outcome variables. *Mod Pathol* 13(5):542-547, 2000.

188. Carlson JA, Healy K, Tran TA, Malfetano JH, Wilson VL, Rohwedder A, Ross JS. Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. *Am J Pathol* 157:973-983, 2000.

189. Kronz JD, Silberman MA, Allsbrook, Jr. WC, Bastacky SI, Burks RT, Cina SJ, Mills SE, Ross JS, Sakr WA, Tomaszewski JE, True LD, Ulbright TM, Weinstein MW, Yantiss RK, Young

RH, Epstein JI. Pathology residents' use of a web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. *Hum Pathol* 31:1044-1050, 2000.

190. Abrahams HM, Graber MW, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman Jr., RP, Ross JS. Prognostic significance of topoisomerase II α overexpression in transitional cell carcinoma of the urinary bladder. *Journal of Urologic Pathology* 13:13-22, 2000.

191. Ross, JS. Judging academic pathology chairpersons. *Am J Clin Pathol* 115:180-181, 2001.

192. Ross JS, Cohen MB. Biomarkers for the detection of bladder cancer. *Advances in Anatomic Pathology*. 8:37-46; 2001.

193. Ross JS. DNA ploidy analysis may facilitate management in cancer patients. *Primary Care and Cancer*. 49-54, 2001.

194. Ross JS and Cohen MB. Detecting recurrent bladder cancer: new methods and biomarkers. *Exp. Rev. Mol. Diagn.* 1(1):39-52, 2001.

195. Carlson JA, Amin S, Malfetano J, Tran TA, Selkin B, Hou J, Goncharuk V, Wilson VL, Rohwedder A, Ambros R, Ross JS. Concordant p53 and mdm-2 protein expression in vulvar squamous cell carcinoma and adjacent lichen sclerosus. *AIMM* 9(2): 150-63; 2001.

196. Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein, Kallkaury BVSK. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. *Am J Clin Pathol* 116:122-128, 2001.

197. Ross JS, McKenna BJ. The HER-2/*neu* oncogene in tumors of the gastrointestinal tract. *Cancer Invest* 19(5):554-568; 2001.

198. Boulos MTB, Rifkin MD, Ross J. Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. *Ultrasound Quarterly* July/September 17(3); 2001.

199. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. *Modern Pathology* 14:672-676; 2001.

200. Kallakury BVS, Sheehan CE, Ross JS. Co-downregulation of cell adhesion proteins α and β catenins, p120CTN, e-cadherin, and CD44 in prostatic adenocarcinomas. *Human Pathology* 32:849-855, 2001.

201. Kallakury BVS, Karikahalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. *Clinical Cancer research* 7:3113-3119, 2001.

202. Ross JS, Greene B. Targeted therapy in oncology: the agony and ecstasy of personalized medicine. *Expert Rev. Anticancer Ther.* 13:321-322, 2001.

203. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis: A cancer of the blood vessels? *Am J Clin Pathol* 116(Suppl 1): S97-S107, 2001.
204. Kallakury BVS, Sheehan CE, Winn-Deen E, Oliver J, Fisher HAG, Kaufman, Jr., RP, Ross JS. Decreased expression of catenine (α and β). P120 CTN, and e-cadherin cell adhesion proteins and e-cadherin gene promoter methylation in prostatic adenocarcinomas. *Cancer* 92(11):2786-2795, 2001.
205. Elliott PJ, Ross JS. The Proteasome: A new target for novel drug therapies. *Am J Clin Pathol* 116:637-646, 2001.
206. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and Cancer: Common molecular pathways of disease development and progression. In *Atherosclerosis VI: The Sixth Saratoga International Conference*, Numan and Gimbrone (eds), 2001, pp 271-293.
207. Stagliano NE, Carpino AJ, Ross JS, Donovan MJ. Vascular gene discovery using laser capture microdissection of human blood vessels and quantitative PCR. In *Atherosclerosis VI: The Sixth Saratoga International Conference*, Numan and Gimbrone (eds), 2001, pp 334-349.
208. Rifkin MD, Li S, Peters TL, Ross JS. Visual inspection of the prostate biopsy specimen: aid to diagnosis and management. *Ultrasound Q.* 17(3);191-196, 2001.
209. Depowski PL, Dunn H, Purdy S, Ross JS, Nazeer T. Splenic marginal zone lymphoma. *Arch Pathol Lab Med*, 126(2):214-216, 2002.
210. Ross JS, Sheehan CE, Fisher HAG, Kauffman R, Dolen EM, Kallakury BVS. Prognostic markers in prostate cancer. *Expert Rev Mol Diag* 2(2):89-102, 2002.
211. Rosenthal SI, Depowski PL; Sheehan CE, Ross JS. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. *Applied Immunohistochemistry and Molecular Morphology*; 10:40-46; 2002.
212. Ross JS, Sheehan CE, Dolen EM, Kallakury BVS. Morphologic and molecular prognostic markers in prostate cancer. *Advances in Anatomic Pathology* 9:115-128, 2002.
213. Goncharuk VN, Ross JS, Carlson JA. Actin-binding protein fascin expression in skin neoplasia. *J Cutan Pathol*;29:400-8;2002.
214. Ross JS, Ginsburg GS. Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. *Expert Rev Mol Diagn* 2(6), 531-41, 2002.
215. Ross JS, Ginsburg GS. The integration of molecular diagnostics with therapeutics: implications for drug development and pathology practice. *Am J Clin Pathol* 119:26-36, 2003.
216. Ross JS. Ancillary techniques applied to cytopathology, Part 1. *Advance Laboratory*, 12(1): 16-17, January 2003.
217. Ross JS. Ancillary techniques applied to cytopathology, Part 2. *Advance Laboratory*, 12(2): 20, February 2003.

218. Ross JS, Kaur P, Sheehan CE, Fisher HAG, Kaufman, Jr. RA, Kallakury BVS. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. *Mod Pathol* 16:198-205, 2003.
219. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Hofler H, Kiechle M, Schmitt M, Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. *J Clin Oncol* 21: 1022-1028, 2003.
220. Ross JS, Gray K, Gray GS, Worland PS, Rolfe M. Anticancer antibodies. *Am J Clin Pathol* 119:472-485, 2003.
221. Carlson JA, Slominski A, Linette GP, Mihm Jr MC, Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis (Part 1). *Expert Rev Mol Diagn* 3(2):163-184;2003.
222. Carlson JA, Slominski A, Linette GP, Mihm Jr MC, Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis (Part 2). *Expert Rev Mol Diagn* 3(3):303-330;2003.
223. Kren L, Goncharuk VN, Votava M, Hermanova M, Ross JS, Nazeer T, Dvorak K. Botryoid-type of embryonal rhabdomyosarcoma of renal pelvis in an adult. A case report and review of literature. *Cesk Patol* 39(1):31-35, 2003.
224. Kren L, Hermanova M, Goncharuk VN, Kaur P, Ross JS, Pavlosky Z, Dvorak K. Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinopathologic study of 100 cases. *Cesk Patol* 39(1):17-20, 2003.
225. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target for therapy. *Oncologist* 8(4):307-325; 2003.
226. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine. *Expert Rev Mol Diagn* 3(5), 2003.
227. Ross JS, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M. Antibody-based therapeutics in oncology. *Expert Rev Anticancer Ther* 3(1):89-103, 2003.
228. Ross JS. Emerging Cancer Diagnostics: "On slide" or "Off slide": That is the question. (editorial). *Am J Clin Pathol* 120:822-4, 2003.
229. Zemzoum I, Kates RE, Schmitt M, Ross JS, Hofler H, Kiechle M, Harbeck N. HER-2 status and UPA/PAI-1 provide complementary information on patient outcome in node-negative breast cancer. *Breast* 12 Suppl 1:S23-4, 2003.
230. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest*. 112:1821-30;2003.

231. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV. Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer. *Clin Cancer Res.* Dec 15;9(17):6357-6362;2003.
232. Ross JS, Linette GP, Stec J, Ross MS, Anwar S, Boguniewicz A. DNA Ploidy and Cell Cycle Analysis in Breast Cancer. *Am J Clin Pathol* 120:S72-S84;2003.
233. Carlson JA, Slominski A, Linette GP, Mysliborski J, Hill J, Mihm MC, Ross JS. Malignant melanoma 2003: Predisposition, diagnosis, staging and prognosis. *Am J Clin Pathol.* 120: S101-S127;2003.
234. Ross JS, Fletcher JA, Bloom K, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai LP, Hortobagyi GN. HER-2/neu testing in breast cancer. *Am J Clin Pathol.* 120:S53-S71;2003.
235. Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HAG, Kaufman RP, Anwar S, Kallakury BVS. Prognostic factors in prostate cancer. *Am J Cklin Pathol* 120:S85-S100;2003.
236. Kaur P, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman Jr, RP, Ross JS. Survivin and bcl-2 expression in prostatic adenocarcinomas. *Arch Pathol Lab Med.* 128:39-43;2004.